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ABSTRACT 
 
To better understand the relationship between allosteric ligand structure and the 
resulting allosteric behavior, we investigated the roles that functional groups and structure 
play in the binding affinity and allosteric potency of ligands at the allosteric site of 
phosphofructokinase from E. coli (EcPFK).  EcPFK is allosterically inhibited and activated 
in the presence of phospho-enol-pyruvate (PEP) and MgADP, respectively.  Both activator 
and inhibitor bind to the same effector site and result in modification of the affinity for the 
substrate fructose-6-phosphate (F6P).  The fact that both MgADP and PEP bind to the same 
binding site using a majority of the same residues, makes EcPFK an ideal system for this 
type of allosteric characterization.  
In order to better understand the structural affects that PEP has on EcPFK, here we 
present the first study of the crystal structure of EcPFK that has been solved with PEP bound 
to the allosteric binding sites (EcPEP).  The disproportionation reaction, EA + XE ↔ E + 
XEA, describes the equilibrium between the two binary complexes, i.e. the enzyme bound to 
substrate (EA) or allosteric effector (XE), on one side of the equilibrium and on the other 
side is the apo enzyme (E) and the ternary complex (XEA), i.e. where both substrate and 
allosteric ligand are bound.  When accounting for the disproportionation equilibrium, the 
known crystal structures of EcPFK can be identified as a specific species and characterized 
independently of the other species.  Given the disproportionation reaction, EcPEP is the only 
known crystal structure of an EcPFK binary complex.  EcATC represents the ternary 
complex while EcApo represents the unbound enzyme. 
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To specifically address the roles of allosteric ligand functional groups, 
thermodynamic linkage analysis was used to examine wild type EcPFK in the presence of 
allosteric ligand analogs.  This analysis allowed for a particular effector ligand functional 
group to be assigned as important to ligand binding, to allosteric coupling, to both binding 
and coupling, or to neither binding nor coupling.  As a complement to the allosteric ligand 
analog study, we used thermodynamic linkage analysis to study EcPFK with mutations in the 
allosteric binding site.  Specifically, position 58 was examined and compared to the allosteric 
ligand analog results. 
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NOMENCLATURE 
 
5-HT3  5-Hydroxytriptamine Receptors 
[A]   Concentration of Substrate / Ligand that Binds Receptor Active Site 
A  Substrate / Ligand that Binds Receptor Active Site 
BsPFK  Phosphofructokinase from Bacillus stearothermophilus 
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Activator 
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ΔHay   Coupling Enthalpy Between Substrate and Allosteric Inhibitor 
ΔSax   Coupling Entropy Between Substrate and Allosteric Activator 
ΔSay   Coupling Entropy Between Substrate and Allosteric Inhibitor 
CEPA  2-Carboxyethylphosphonic Acid 
CML  Chronic Myeloid Leukemia 
E  Enzyme 
EA  Binary Complex of Enzyme and Substrate 
EcApo  Crystal Structure of apo EcPFK 
EcATC Crystal Structure of the Activated Ternary Complex of EcPFK Bound to FBP, 
MgADP (Catalytic Site), and MgADP (Allosteric Site). 
ECD  Extracellular Domain 
ECL  Extracellular Loop 
 vii 
 
EcPFK  Phosphofructokinase from Escherichia coli 
EcPEP  Crystal Structure of EcPFK Bound to PEP 
EDTA   Ethylenediamine Tetraacetic Acid 
EPPS   N- [2-Hydroxyethyl] Piperazine--3-Propanesulfonic Acid 
F6P   Fructose-6-Phosphate 
FBP  Fructose-1,6-Bisphosphate 
GABAA γ-Amino Butyric acid A Receptor 
GABAB γ-Amino Butyric acid B Receptor 
GPCR  G Protein-Coupled Receptor 
GDP  Guanosine 5’-Diphosphate 
GlyR  Glycine Receptors 
GTP  Guanosine 5’-Triphosphate 
ICD  Intracellular Domain 
ICL  Intracellular Loop 
Ka  Apparent Dissociation Constant of A 
Kd  Dissociation Constant 
Kia°   Dissociation Constant of A in the Absence of Allosteric Ligand 
Kia∞  Dissociation Constant of A in the Saturating Presence of Allosteric Ligand 
Kix°  Dissociation Constant of Allosteric Activator in the Absence A 
Kix∞ Dissociation Constant of Allosteric Activator in the Saturating Presence of A 
Kiy°  Dissociation Constant of Allosteric Inhibitor in the Absence of A 
Kiy∞  Dissociation Constant of Allosteric Inhibitor in the Saturating Presence of  
A 
LGIC  Ligand Gated Ion Channels 
MgADP Magnesium2+ Adenosine 5’-Diphosphate 
MgATP Magnesium2+ Adenosine 5’-Triphosphate 
Mg-dADP  Magnesium2+ 2’-Deoxy-Adenosine Diphosphate 
MgAMPCP α-β-Methylene-Adenosine Diphosphate 
MgGDP  Magnesium2+ Guanosine 5’-Diphosphate 
MgIDP Magnesium2+ Inosine 5’-Diphosphate 
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MgUDP Magnesium2+ Uridine 5’-diphosphate 
MOPS  3-[N-Morpholino] Propanesulfonic acid 
nAChR Nicotinic Acetylcholine Receptors 
NADH  Nicotinamide Adenine Dinucleotide, reduced form 
PDB  RCSB Protein Data Bank 
PEP   Phosphoenolpyruvate 
PFK   Phosphofructokinase 
PG   Phosphoglycolate 
Pi  Inorganic Phosphate 
PMAA  Phosphonomethylacrylic Acid 
PPA  Phosphonoacetic Acid 
PTH  Parathyroid Hormone 
PTK  Protein Tyrosine Kinase 
Qax  The Coupling Quotient between A and X 
Qay  The Coupling Quotient between A and Y 
RMSD  Root-Mean-Square Deviation 
RTK  Receptor Tyrosine Kinase 
T  Temperature 
TM  Transmembrane Domain 
TMH  Transmembrane Helix 
TK  Tyrosine Kinase 
Tris   Tris [Hyroxymethyl] Aminomethane 
v◦  Initial velocity 
V   Maximal velocity 
[X]   Concentration of Allosteric Activator 
X   Allosteric Activator 
[X’]   Concentration of Allosteric Activator Analog 
X’   Allosteric Activator Analog 
XE  Binary Complex of Enzyme and Allosteric Activator 
XEA  Ternary Complex of Enzyme, Allosteric Acitvator, and Substrate 
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[Y]   Concentration of Allosteric Inhibitor 
Y   Allosteric Inhibitor 
[Y’]   Concentration of Allosteric Inhibitor Analog 
Y’  Allosteric Inhibitor Analog 
YE  Binary Complex of Enzyme and Allosteric Inhibitor 
YEA  Ternary Complex of Enzyme, Allosteric Acitvator, and Substrate 
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1. INTRODUCTION  
 
 
 
Each year an estimated $67 billion dollars is spent on research and development for 
new drugs (1), and an estimated cost of $1.3 billion is spent for the development of each new 
drug (1).  Given the large investments applied towards research and development, the 
pharmaceutical industry is always on the lookout for better drug design strategies.  Drug 
design based on allosteric phenomena may provide better strategies than more simple 
alternatives such as substrate competition.  For example, if a disease related protein could be 
inhibited or activated through allosteric control, a strategy taking advantage of this could 
grant a greater degree of control over a given physiological system.  In the scenario where a 
physiological molecule is used as a substrate by a variety of proteins, the use of allosteric 
ligands as the model for drug design may provide an opportunity for greater specificity and 
selectivity in protein targeting.  The use of an allosteric ligand also has the advantage of 
providing control over a protein’s maximal velocity and/or substrate affinity, which can limit 
side effects and overdosing (2).  Allosteric effector ligands modify the behavior of a given 
protein instead of attempting to compete with enzymatic substrates, providing the possibility 
of fine tuning medical conditions using pharmaceutical treatments. 
Cell surface receptors have been increasing in popularity as targets for drug design.  
This complex group of proteins is diverse in physiological function yet maintain many 
similarities to one another.  Cell surface receptors are often split into 3 major classes: G 
protein-coupled receptors (GPCRs); ligand-gated ion channels (LGICs); and tyrosine kinases 
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(3, 4).  A general description of all classes of cell surface receptors is a membrane protein 
that exhibits a function when triggered by the binding of the appropriate ligand to a binding 
site termed the orthosteric site.  The orthosteric site is somewhat analogous to the catalytic 
site of an enzyme in that it serves to bind the ligand responsible for protein function.  In cell 
surface receptors the orthosteric site does not catalyze chemical reaction, but instead 
catalyzes the triggering of the receptor’s function.  Hereafter, the orthosteric site will be 
referred to as the receptor’s active site.  Recent studies on the allosteric properties of these 
receptors allow researchers to form libraries of allosteric ligands.  The data gathered have 
revealed a greater diversity of allosteric ligands (hereafter referred to as X) than that of the 
ligands that bind the receptors’ active sites (hereafter referred to as A).  The knowledge 
gained about cell surface receptor allostery and its diversity has enabled the design of drugs 
with greater specificity in drug targeting, even among the isoproteins within the individual 
super-families (5).  In an effort to display the necessity of understanding allostery, this 
chapter will review the major classes of cell surface receptors along with allosteric drugs that 
have been shown to modulate their function.   
 
Allosteric Study in Receptors 
Structurally, cell surface receptors possess three domains; an extracellular domain 
(ECD) for interaction with ligand A, a transmembrane segment (TM) for signal transmission 
through the membrane, and an intracellular domain (ICD) for which to propagate a response.  
Though the four main classes of receptors vary in their overall physiological roles, they all 
display this basic morphology and therefore utilize very similar functional mechanisms.  
Since receptors do not catalyze chemical reactions, a simple description of this mechanism is 
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as follows: A binds to the active site of the receptor commonly located in the ECD or TM; 
the binding of A triggers a structural change in the receptor; and the structural change allows 
for either the up or down regulation of receptor function.  For example, LGICs allow the 
passing of a particular ion through a channel in the protein when ligand A is bound.  In other 
words, the binding of ligand A catalyzes the passage of ions through the protein channel of 
ligand gated ion channel receptors. 
The functional mechanism is often explained by the two common enzymatic models, 
induced fit and conformer stabilization.  Induced fit, in this scenario, presumes that the 
receptor exists in a preferred structural conformation and ligand A, when bound, forces the 
protein to modify its structure in order to accommodate it (6).  In turn, the ligand induced 
change then modifies receptor function.  Conformer stabilization, however, says that the 
receptor is constantly sampling numerous structural conformations at random.  In the event 
of conformer stabilization, a change in receptor function is seen when ligand A preferentially 
binds to the relevant conformer, thereby selecting it as the primary conformation.  In either 
case, when the binding of A causes a receptor to produce or increase the production of 
receptor function ligand A is termed an agonist.  When a receptor displays a constitutive 
function that is decreased or stopped, A is termed an inverse agonist.  A third scenario exists 
where A binds but does not cause a change in receptor function.  These types of ligands are 
called neutral agonists and will not be addressed any further. 
Much of the research on receptors has focused on the illumination of the functional 
mechanism for the individual families.  As a result, ligand A analogs were the focus of drug 
design when it came to receptors.  During the last decade, however, research has shifted 
toward the allosteric modulation of the functional mechanism.  This phenomenon is 
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displayed when a ligand binds to a site that is separate and distinct from the active site of a 
receptor, the allosteric site, and causes a modulation in the ability of A to change the receptor 
function. 
Many receptors have been shown to exhibit allosteric events that modulate receptor 
function (2, 5, 7-12).  Allosteric ligands have been shown to affect receptor function 
triggered by ligand A in both positive and negative manners.  When an allosteric ligand, X, 
increases the efficacy of ligand A it is termed an activator and an allosteric ligand with a 
negative impact on the efficacy of A is an inhibitor.  Referring to the LGIC example given on 
the previous page, the binding of X modifies the efficacy by which ligand A triggers the 
passage of ions through the receptor.  Efficacy of ligand A is affected by the allosteric ligand 
modifying ligand A affinity and/or the modification of ligand A regulated receptor function.  
Such modulations are described more commonly by the Ternary Complex Model (TCM), 
which was first proposed to be used in the description of receptors by Lefkowitz et al. and 
explored more thoroughly by Ehlert (2, 13, 14).
 5 
 
 
Figure 1-1: a) A diagram for the thermodynamic box representing single substrate, 
single effector scheme.  b) The equilibrium equation for the disproportionation 
reactions implied by the thermodynamic box in A (15, 16). 
 
 
 
Equation 1-1: The coupling quotient (Qax or Qay) as defined by the apparent 
dissociation constant of ligand A (in the absence and saturating presence effector X) 
and the apparent dissociation constant of effector X (in the absence and saturating 
presence ligand A). 
 
 
 
Equation 1-2: The relationship of the coupling quotient (Qax or Qay) to the free energy 
of coupling (17). Note that ΔGax is a standard state free energy (ΔG°) and that we have 
deviated from the standard notation. 
E
X
A EA!
XE! XEA!
+
+
+
+
A
X
Kiaº!
Kix∞!Kixº!
Kia∞!
E
XE!
P!
P!
+
+
EA! XE! XEA! E!+! +!
Qax!
a! b!
Kiao/Kia∞ = Kixo/Kix∞ = Qax !
∆Gax = -RTlnQax!
Kiao/Kia∞ = Kixo/Kix∞ = Qax !
∆Gax = -RTlnQax!
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The nature and magnitude of an allosteric response is better described by 
thermodynamic linkage analysis (15, 16).   Here, we will apply this analysis to a single-
substrate-single-effector kinetic scheme (Figure 1-1) (17).  The scheme used assumes that A 
and X bind at two separate and distinct binding sites on the receptor (E).   The scheme 
provides for two distinct dissociation constants for each ligand, A or X, found in the absence, 
Kia° and Kix°, and in the saturating presence, Kia∞ and Kix∞, of the other, respectively (15, 
16). The scheme shows the dependence of Kia on [X].   The thermodynamic box implies a 
reciprocity to the linkage that exists between the substrate and effector ligand.   The energy 
required to reach the ternary complex (XEA) is independent of the path taken, meaning 
KiaoKix∞=KixoKia∞.   The constants can then be rearranged into Kiao/Kia∞=Kixo/Kix∞ (Equation 
1-1) which we use to define the coupling quotient (Qax) (15, 16).  Qax represents the nature 
and magnitude of an allosteric phenomenon, enabling a much more complete characterization 
of a given allosteric interaction.   In the case of an activator, Qax will have a value greater 
than one, and for an inhibitor its value is less than one (Equation 1-1) (18).   Qax also 
represents the thermodynamic equilibrium of the disproportionation reaction given in Figure 
1-1 and described by equation 1-1 (15-17).  Since Qax is an equilibrium constant, it can be 
used to calculate the free energy of coupling between A and X by equation 1-2. 
Modified versions of the thermodynamic linkage model are highly utilized in the 
detection allosteric modulators in drug development.  Due to the simplicity of the model, it 
can easily be incorporated into common drug research assays, such as radiolabeled probe 
assays, which are already prominent in the field of receptor studies (2).  There are two 
aspects of thermodynamic linkage analysis that allow for its ease of application.  The first 
aspect is the existence of reciprocity between A and X.  Although X is perceived to be 
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allosterically modulating A, thermodynamic linkage analysis states that A is equally 
modulating X.  In this scenario reciprocity allows a certain degree in freedom in 
experimental design but more importantly allows the second assumption.  The second 
important aspect is that the effect of allostery on binding affinity is shown to be separate 
from the allosteric effect on efficacy of the functional mechanism. 
 
G Protein-Coupled Receptors 
The largest class of cell surface receptors is the G protein-coupled receptor (GPCR) 
superfamily with well over 1000 members (19).  G proteins are heterotrimeric guanine 
nucleotide binding proteins that interact with and regulate intracellular targets in response to 
extracellular signals.  GPCRs are known to be involved in the physiological functions of 
taste, smell, and sight via their recruitment and regulation of G proteins (3).  G proteins have 
3 subunits that are denoted as α, β, and γ.  When the α subunit is bound to guanosine 
diphosphate (GDP) it binds to the intracellular carboxy-terminus of a GPCR.  The general 
functional mechanism of a GPCR begins with the binding of ligand A, a neuropeptide or 
peptide hormone, to the active site.  Once bound the GPCR changes conformation, which is 
then propagated through the plasma membrane and to the G protein α subunit.  The 
conformational shift of the G protein now allows for the dissociation of GDP followed the 
binding of GTP.  Once GTP is bound the α subunit dissociates from the GPCR and the other 
G protein subunits.  The left over subunits now  
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Figure 1-2: Representation of a GPCR showing seven transmembrane helices (TMH), 
three extracellular loops, three intracellular loops, the α G-protein bound to the C-
terminus region in orange, the β G-protein in green, and the γ G-protein in yellow. The 
disulfide link between ECL1 and ECL2 is represented in red.  
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form the βγ G protein and go on to interact with intracellular targets along with the GTP 
bound α G protein.  Once the α subunit associates with various targets that can hydrolyze the 
GTP to GDP, the α reassociates with βγ and the GPCR carboxy-terminal (3).   
GPCRs exist as homo and hetero pentamers.  The major structural characteristic of 
GPCRs is the possession of 7 transmembrane helices (TMH).  The monomeric proteins are 
oriented so that the amino-terminals are extracellular and the carboxy-terminals are 
intracellular.  GPCRs also possess 3 extracellular and 3 intracellular loops (ECL and ICL, 
respectively).  Another overall GPCR characteristic is a conserved disulfide link between 
ECL1 and ECL2 (Figure 1-2) (19).  As a whole the GPCR superfamily shares little sequence 
homology, except when it is sub-divided into families (19).  Most commonly, GPCRs are 
divided into 3 families using phylogenetics and sequence homology (20). 
Class A, Rhodopsin-Like Receptors, is the largest GPCR family with over 800 
members (20, 21).  Overall sequence homology among class A GPCRs is still low with the 
exception of an Aspartate-Arginine-Tyrosine (DRY) motif that appears in ICL2 (20).  Class 
B, Secretin-Like Receptors, is considerably smaller with around 40 receptors.  This family is 
characterized by a larger amino terminus containing several, highly conserved, cysteine 
residues (20, 21).  Last is Class C, Metabotropic and γ-Amino Butyric Acid Receptors.  This 
group consists of around 200 members and is characterized by a 500-600 residue amino-
terminus, the largest of the GPCRs.  The ECD of class C GPCRs is predominantly comprised 
of the amino-terminus.  This large ECD is often described as a venus fly trap of which the 
ligand A binding site lies in the middle (12, 20).   
Cell Surface receptors are thought to be the target for more than 40% of the nearly 
1400 unique drugs that have been approved by the FDA (22).  Of that 40%, GPCRs account 
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for 67% of the targets. In fact, the last 25 years of research have shown drugs like aspirin, 
heparin, and zinc to be allosteric modulators of GPCRs and they have been in use for decades 
(12).  However, as stated previously, there are many new allosteric drugs in development that 
are targeted towards cell surface receptors.  One example of the relatively new drugs is 
maraviroc. 
Maraviroc is an allosteric inhibitor of the chemokine receptor CCR5 (23).  CCR5 is a 
Class A GPCR that is expressed in T-cells and other leukocytes, and is involved in the 
chemotaxis of these cells.  CCR5 ligands are the chemokines RANTES, MIP-1β, MIP-1, and 
MIP-2 (24).  This particular chemokine receptor, along with CXCR4, has garnered a great 
deal of attention in recent years due to their participation in the HIV-1 infection process.  
This attention has also been driven by the discovery of the non-life threatening variant 
CCR5Δ32.  Many of the common HIV-1 strains utilize CCR5 and/or CXCR4 as co-receptors 
to gain cell entry.  The CCR5Δ32 variant is a 32 base pair deletion in the gene of CCR5 that 
results in the premature termination of CCR5 production.  CCR5Δ32 results in receptor 
proteins terminated between TMH4 and TMH5.  The end result of this deletion is an absence 
of CCR5 expression and a highly HIV-1 resistant homozygous population (23, 25).  
Traditional drugs, such as competitive inhibitors, that have been investigated for CCR5 
inhibition have been discouraging due to a lack of finite specificity.  CCR5 belongs to sub-
family of 19 total receptors that bind to chemokines, resulting in a high degree of sequence 
homology in the extracellular orthosteric ligand binding site (21).  In this case a drug that 
does not have a high specificity for just CCR5 can cause severe immune depression by 
inhibiting other critical receptors such as CCR2 and CXCR4 (23).  Maraviroc has displayed 
the characteristics of a typical allosteric inhibitor for GPCRs and has shown the ability to 
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selectively inhibit only CCR5 (23).  This type of allosteric regulation allows patients to 
effectively display the Δ32 phenotype while allowing normal immune function to continue 
(23).  Maraviroc displays a potential strength for all allosteric drugs in the ability to regulate 
a specific protein without affecting its homologous family members. 
Cinacalcet is another example of allosteric strengths utilized in GPCR drug function.  
Cinacalcet is a known allosteric activator of Calcium Sensing Receptor (CaSR) (26).  CaSR 
is member of Class C GPCRs and is responsible for the monitoring and regulation of calcium 
in the body.  CaSR are located on the surface of parathyroid chief cells and are bound to Ca2+ 
when they are non-functional.  When serum Ca2+ levels become too low Ca2+ dissociates, 
triggering CaSR to release parathyroid hormone (PTH) (26).  PTH acts to increase Ca2+ 
levels by stimulating the reabsorption of calcium from bone and kidney filtrate.  High serum 
Ca2+ levels are commonly caused by secondary hyperthyroidism, and often seen in patients 
with reduced kidney function (26).  Since Cinacalcet is an allosteric activator of CaSR it is 
often used to treat such patients in order to increase sensitivity of CaSRs calcium detection.  
In other words, cinacalcet better enables CaSR to do its job.  Drugs like cinacalcet attempt to 
allow the body’s natural regulation to control Ca2+ instead attempting to take over Ca2+ 
homeostasis via multiple drugs or treatments (27).   
 
Ligand Gated Ion Channels 
Ligand gated ion channels (LGIC) were first isolated from the electric organ of 
Electrophorus electricus in 1970 (28).  Since their discovery, LGIC receptors have been 
shown to express in every animal cell and proven to be a necessity in brain function due to 
their regulation of ion passage through membranes.  Although the majority of cells express 
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LGICs in small numbers, they can cover nearly 50% of nerve cell membranes (29).  Given 
their function and population density on nerve cells it comes as no surprise that LGICs are 
critical in fast synaptic transmission.  The basic mechanism of LGIC receptor function is the 
binding of a neurotransmitter to the active site in the ECD, triggering a conformational shift 
that opens the receptor pore allowing ions to pass (30).   
LGICs can be structurally quite different and are sub-divided based on these structural 
differences alone.  Commonly, there are 3 super-families; the cys-loop superfamily, the ATP 
gated channel superfamily, and the glutamate activated cationic susperfamily (31).  Given 
that LGICs traffic ions they are all also recognized as being either excitatory-cation selective, 
or inhibitory-anion selective (10).   
Cys-loop receptor superfamily is the largest of the three LGIC superfamilies and will 
be the only superfamily discussed further.  All the LGICs are homo and/or hetero oligomeric 
channels, with the families often discussed in terms of their monomeric proteins that form the 
channels (10, 32).  The cys-loop superfamily contains 47 identified monomeric proteins that 
form 5 types of homo/hetero pentameric channel receptors.  Each type of receptor utilizes a 
specific number and set of monomeric proteins as subunits.  Nicotinic acetylcholine receptors 
(nAChR) use 17 monomers while 5-hydroxytriptamine receptors (5-HT3), zinc activated 
channels (ZAC), γ-amino butyric acid A and B receptors (GABAA and GABAB), and glycine 
receptors (GlyR) use 5, 1, 19, and 15 subunits, respectively (31, 32).  Of this superfamily 
only the GABA receptors and GlyR are anion selective, while the remainder of superfamily 
is cation selective.  All cys-loop receptors retain a characteristic loop in the ECD, composed 
of the amino-terminus.  This “Cys-Loop” is a 13 residue segment flanked by 2 cysteine 
residues that form a disulfide bond with one another.  The rest of the ECD, which contains 
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the active sites, is primarily composed of β-sheets.  The 3 LGIC superfamilies all have a 
different number of transmembrane segments and the cys-loop superfamily has 4 
transmembrane helices that help form the ion channel (30).  The carboxy-terminus structure 
composing the ICD is largely unknown except for the existence of an α-helix that resides at 
the opening of the channel pore (Figure 1-3). 
With GPCRs supplying the targets for 67% of the 40% cell surface receptor drugs, the vast 
majority of the remaining 33% are targeted towards ligand LGICs (22).  Drugs targeted 
towards LGICs are known to treat disorders and diseases such as epilepsy, insomnia, nicotine 
addiction, ADHD, depression, and Crohn’s disease (33).  The disorders and diseases listed 
are thought to be caused by genotypes that cause channels to open too slowly, close to slowly 
or close to quickly (33).  Since the purpose of allostery is to regulate proteins, allosteric drugs 
are the logical choice for treatment of LGIC disorders. 
With a large number of subunits belonging to each LGIC superfamily, the formation 
of heteromeric channels is common.  LGICs are able to somewhat differentiate themselves 
physiologically from one another due to their active sites being located at the subunit 
interfaces making multiple configurations possible.  With the variety of possible 
configurations it is not uncommon to see some active sites serving as allosteric sites and lose 
the ability to directly trigger channel gating (11).  The subunit that contributes the majority of 
the ligand binding site is called the principal subunit.  The subunit that contributes the 
remaining portion of the binding site is termed the complementary subunit (30).   
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Figure 1-3: Representation of the Cys-Loop superfamily of ligand gated ion channel 
showing the Cys-loop in green, four transmembrane helices (TMH) in blue, an 
extracellular domain (ECD) in purple, and an intracellular domain (ICD) in red.
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Figure 1-4: a) Idealized representation of receptor monomer grouping, b) Top down 
view of receptor monomers α, β, and γ. The αβ ligand A binding sites are comprised of a 
yellow α portion and a red β portion.  The αγ allosteric site is comprised of a yellow α 
portion and a green γ portion. 
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The interaction of benzodiazepines with the αβγGABAA receptor, member of the cys-
loop superfamily, is considered a classic example of allosteric sites derived from former 
active sites (12, 32).  αβγGABAA receptors are inhibitory anion selective receptors and are 
most common GABAA subtype found in the brain (34).  Benzodiazepines have been 
approved drugs and on the market for over 50 years.  Just a few examples are alprazolam 
(Xanax), clonazepam (Klonopin), and diazepam (Valium).  Benzodiazepines are used to treat 
a very long list of afflictions that includes epilepsy, anxiety disorders, sleep disorders, and 
skeletal muscle pain/spasms (34-36).   
The αβγGABAA receptor is composed of two α, two β, and one γ GABAA subunits 
and ordered as shown in figure 1-4.  The active site is formed at the βα interface, that is 
where β is the principal and α is the complementary subunit.  The allosteric site, or 
benzodiazepine binding site (BZ) in this scenario, is located at the αγ interface, where α now 
serves as the principal subunit.  The γ subunit, unlike the β subunit, prevents the ligand 
binding site formed with the α subunit from directly triggering receptor function, but allows 
it to function as an allosteric site.  This composition and arrangement of subunits yields 2 
active sites and one allosteric site (11).  When benzodiazepines are bound to the αγ ligand 
binding site they have been shown to modulate both active site affinity for ligand A and the 
ability of ligand A to trigger receptor function (2, 34, 37).  More recently studies have been 
attempting to parse out the residues involved in binding specificity and allosteric modulation 
in order to design better and more specific benzodiazepines (34).   
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Tyrosine Kinases 
The third and last major group of cell surface receptors is the tyrosine kinase (TK) 
superfamily.  This superfamily has gained a substantial amount of attention since their 
discovery in 1980 (38).  TKs are subdivided into two superfamilies; receptor tyrosine kinases 
(RTK) and protein tyrosine kinases (PTK).  TKs possess a large amino-terminus that 
composes the ECD along with the active site.  Displaying the least number of transmembrane 
segments out of all receptors discussed, RTKs only possess one.  The carboxyl-terminus is 
intracellular and contains a catalytic site which displays tyrosine phosphorylating activity 
(Figure 1-5a) (3).  Although the description just given is true for TKs, stipulations must be 
made for PTKs.  Unlike RTKs, PTKs rely on their close association with cytokine receptors.  
PTKs are analogous to the catalytic portion of RTKs, while cytokine receptors are analogous 
to the transmembrane and receptor portions of RTKs.  The physiological mechanism of the 
heteromeric receptor is also analogous to RTK (3).  For the purposes of this discussion, an 
RTK monomer is comprised of a single protein and a PTK monomer is comprised of two 
proteins, a membrane/transmembrane subunit and a catalytic subunit.   
Despite the slight difference in structural composition, these two families function 
with extremely similar mechanisms and will be assumed identical for the following 
discussion.  TKs utilize multiple controls in order to assure control over their cellular 
functions.  The first of these controls is that TKs exist in the membrane as monomers when 
unbound by active site ligand.  When the appropriate cell signal molecule binds the receptors, 
it induces dimerization.  The active site signaling ligand acts as a cross-linker as well as an   
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Figure 1-5a: Representation of the Tyrosine Kinase superfamily of ligand gated ion 
channel showing one transmembrane helix in blue, the extracellular domain in purple, 
and the intracellular domain in red. Orange rectangle represent potential 
phosphorylation sites.
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allosteric ligand to promote dimerization and therefore induce activation (3, 39).  Once 
activated TKs autophosphorylate one another twice within their ICDs (Figure 1-5b).  Once 
on a loop in the catalytic domain called the activation loop, to increase kinase activity, and 
again outside the catalytic domain to create a binding site for intracellular signaling proteins 
(3).  Autophosphorylation for increased catalytic activity is a result from a ligand activated 
receptor dimer and is thought to help auto-inhibit in the event of a random dimerization (39).   
TKs have been shown to play crucial roles in cell growth, proliferation, 
differentiation, and immune response.  The development of cancer has been described as an 
imbalance between cell cycle progression, mass, and apoptosis (40).  Given the two previous 
statements it is no wonder that mutations in TK genes make up a large group of oncogenes 
(41).  Even the discovery of TKs is because of research to identify oncoproteins (38). 
Imatinib (Gleevec), and many of its derivatives, is an FDA approved drug that specifically 
targets certain TKs (42-44).  Imatinib has been shown to only affect the tyrosine kinases 
designated as Abl, Kit, and PDGFR (45, 46).  Imatinib targets the catalytic component of 
TKs and is considered a selective ATP competitive inhibitor.  Imatininb is considered to be 
selective due to its high affinity and interaction with a hydrophobic pocket adjacent to the 
catalytic site.  Imatininb has also been deemed an ATP competitive inhibitor since the 
hydrophobic pocket is so close to the ATP binding site that it can utilize the nucleotide 
binding portion for its own association (45, 46).  Once bound, the drug “locks” the kinase in 
an unactivated conformation.  This conformation causes the previously mentioned activation 
loop, which is known to be somewhat free moving, to pull into the catalytic site and interact 
with the residues that are key in ATP phosphate binding.   
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Figure 1-5b: Representation of an activated Tyrosine Kinase superfamily of ligand 
gated ion channel. The green diamond represents ligand A binding to a dimer of the 
receptor proteins.  Yellow stars represents the phosphorylation of the intracellular 
domain. 
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The presence of imatinib and the conformational shift it causes effectively closes the active 
site preventing the binding of ATP and therefore unregulated kinase activity (44, 45).   
Chronic Myeloid Leukemia (CML) is a cancer associated frequently with a 
translocation event that creates the “Philadelphia Chromosome” (Ph).  This chromosome 
contains the breakpoint cluster region Ableson oncogene (BCR-ABL).  This gene yields the 
fusion protein Bcr-Abl.  Bcr-Abl is a deregulated PTK with constitutive kinase activity 
belonging to a normal Abl PTK (44, 47).  Given that a portion of the fusion protein is Abl 
made imatinib the logical drug choice.  However, nearly all CML patients who were Ph+ 
developed imatinib resistance, via point mutations in the Bcr-Abl protein, allowing the 
cancer to rebound (43, 44, 48).  The point mutations that occurred were all within the 
hydrophobic binding pocket utilized in imatinib binding.  The appearance of the Bcr-Abl 
point mutations stimulated a search for redesigned imatinib and possibly a drug with an 
alternative inhibitory action.  In recent publications two drugs, GNF-2 and GNF-5, were 
shown to use the native Bcr-Abl binding sites for myristate as an allosteric site (43).  This 
research showed that GNF-2/5 could strongly activate the binding of imatinib to a 
hydrophobic pocket next to the Bcr-Abl catalytic site in all but one of its known hydrophobic 
mutations.  GNF-2/5 could diminish mutant Bcr-Abl activities equal to that of imatinib with 
the native Bcr-Abl.  The T315I mutation, dubbed the “gatekeeper” mutation, is located 
within the ATP binding site of Bcr-Abl.  T315I disrupts a hydrogen bond that is extremely 
important to imatinib binding.  The gatekeeper mutation decreases GNF-2/5 affinity by half, 
relative to wild type, and a maximum 20% inhibition relative to the other Bcr-Abl mutations 
studied (43).   
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The Current Study 
In the previous discussion there have been examples of allosteric drugs that display 
great advantages over typical competitive analogs.  Cinacalcet and maraviroc both impact 
efficacy by increasing and decreasing it, respectively.  In particularly, maraviroc shows high 
selectivity among its most homologous family members.  The benzodiazepines which show 
specificity of target and highlight the fact that allosteric drugs have been in use for decades.  
Lastly, is the ability of GNF-2/5 to allosterically regulate the binding of imantinab.  With the 
majority of these drugs being discovered in the last 2 decades, the drug development industry 
appears to be trending towards the development of allosteric drugs (11, 27, 42, 49, 50).   
Important steps in drug design for cell surface receptors came due to advances in 
fundamental research.  As displayed by the imatinib and GNF2/5 research, understanding the 
underlying biochemical and biophysical mechanisms of a target cannot and should not be 
avoided.  Even though GNF-2/5 was presented as a solution, the Zhang et al. expressed 
confusion and intrigue as to why the gatekeeper mutation has a low maximal effect (43).  
Further, Zhang et al. hypothesized that the gatekeeper residue could be somehow coupled to 
GNF-2/5 binding but also concluded that the gatekeeper residue simply does not favor the 
inactivate conformation (43).  The utilization of fundamental research in drug design can 
release investigators from oversimplifications and preconceived models that are the basis of 
modern high throughput screening drug design.  The current high throughput approach to 
development still takes between 10 to 15 years for a drug to go from screening to FDA 
approval (51).  Given the amount of time spent in development it may come as no surprise 
that the average cost of drug development is steadily increasing.  The cost to develop 
increased over 2-fold from the years 1987-2001 but nearly achieved the same increase from 
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2001-2005 (1).  While there is no doubt that, in a fast paced industry, high throughput design 
has great merit, there has never been a more obvious need for a thorough understanding of 
allostery.  More specifically, there is a need to better understand the effect of allosteric ligand 
structure on the characteristics of the resulting allosteric behavior.  The relationship between 
ligand structure and allosteric function is key to the advancement of allosteric based 
pharmaceutics.   
Here I attempt to better understand the relationship between allosteric ligand structure 
and the resulting allosteric behavior by investigating the roles that functional groups and 
structure play in the binding affinity and allosteric potency of ligands at the allosteric site of 
phosphofructokinase from E. coli (EcPFK).  EcPFK catalyzes the conversion of fructose-6-
phosphate (F6P) into fructose-1,6-bisphosphate (FBP) via phosphoryl transfer from MgATP. 
EcPFK is allosterically inhibited and activated in the presence of phospho-enol-pyruvate 
(PEP) and MgADP, respectively. EcPFK also displays very strong homotropic coopertivity 
towards F6P when MgATP is bound.   Both activator and inhibitor have been shown to bind 
to the same effector site and result in only K-type effects.  The fact that both MgADP and 
PEP bind to the same binding site using a majority of the same residues, makes EcPFK an 
ideal system for this type of allosteric characterization.   
In chapter II, I describe a study of the crystal structure of EcPFK that has been solved 
with PEP bound to the allosteric binding sites (EcPEP).  Over the years, the two state model 
has been relied upon to explain allosteric behavior of EcPFK.  The use of the two state model 
has seemingly been justified due to the two published crystal structures of EcPFK and the 
earlier crystal structures of its homolog, B. stearothermophilus PFK (BsPFK) (52-54).  The 
known EcPFK publications represent the enzyme in the apo form (EcApo) and the activated 
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ternary complex form (EcATC).  The EcATC is bound to FBP and MgADP in the active site, 
as well as MgADP in the effector site (55, 56).  Thermodynamic linkage analysis allows the 
consideration of the enzymatic forms set forth by the disproportionation equilibrium in figure 
1-1b.  In the scheme presented in figure 1-1b, E represents the apo form of an enzyme; XEA 
(or YEA if an inhibitor) represents the ternary complex between allosteric ligand (X or Y), 
enzyme (E), and substrate (A); EA represents the binary complex between enzyme and 
substrate; and XE represents the binary complex between allosteric ligand and enzyme.  For 
EcPFK, only two of these enzymatic complexes have had their crystal structures solved and 
reported.  EcApo represents E in the disproportionation equation and EcATC represents the 
only ternary complex, XEA, reported for EcPFK.  Chapter II presents the first study of the 
YE complex of EcPEP and the first reported crystal structure of any EcPFK and allosteric 
ligand binary complex. 
Chapter III is a thorough kinetic characterization of the coupling between fructose-6-
phosphate (F6P) and allosteric effector analogs.  The resulting study suggests the role of 
functional groups belonging to allosteric ligands.  Different effector analogs that vary only 
slightly from the natural allosteric effectors of EcPFK were utilized.  The minor 
modifications of effector analog relative to effector, allow for meaningful comparisons of the 
parameters obtained via thermodynamic linkage analysis with F6P and allosteric ligand.   
Comparison of dissociation constants (Kd) between the effectors and effector analogs allows 
for a direct analysis of the affects on binding affinity by the variation present, whereas the 
comparison of the coupling quotient (Qax) yields the impact on allosteric response.  Chapter 
III further interrogates the interactions between ligand and protein via modification of 
effector site residues.  In effect, one could reason that the ligand analog study mentioned in 
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the previous paragraph entailed the “mutation” of effector ligands in order to differentiate the 
functional constituents from their molecular structure.   Using the information obtained from 
the ligand analog study along with what is known about the effector binding site, more 
conclusions were made about ligand-residue interactions in the effector site.  Modification of 
ligand interacting residues results in altered allosteric response in a manner comparable to 
those seen with the modified effectors and wild type enzyme.    
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2. CRYSTAL STRUCTURE  
 
 
 
Introduction 
Glycolysis is a very important metabolic pathway that is responsible for converting 
glucose to pyruvate.  This conversion creates ATP and NADH which is needed for cellular 
function.  The first committed step of glycolysis is catalyzed by the allosteric enzyme, 
phosphofructokinase (PFK).  PFK from Escherichia coli (EcPFK) is a long standing and well 
established model for the study of allosteric phenomena.  EcPFK is catalytically active as a 
homotetramer with each monomer comprised of 320 amino acids.  The tetramer is 
approximately 140kDa in size and has four identical catalytic sites and four identical 
allosteric sites that all lie on the interfaces between monomers (57).  EcPFK is inhibited by 
the glycolytic product phospho-enol-pyruvate (PEP) and activated by its product MgADP.  
Both PEP and MgADP produce K-type effects only.  EcPFK catalyzes a phosphoryl transfer 
from ATP to convert fructose-6-phosphate (F6P) into fructose-1,6-bisphosphate (FBP). The 
symmetry and relative simplicity of EcPFK combined with thermodynamic linkage analysis 
allows the use of a single substrate, single modifier scheme for characterization (15, 16, 58).  
EcPFK analysis in this manner allows for the assignment of meaningful allosteric 
parameters.  For example, the coupling quotient (Q) depicts the nature and the magnitude of 
a particular allosteric interaction (15, 16).  This same symmetry, however, also lends itself to 
preconceived assumptions and models as concluded in the original EcPFK characterization in 
1968 (57).  The conclusion of Blangy et al. used the simplicity of a one substrate, one 
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modifier model to suggest that the allostric properties of EcPFK can be qualitatively and 
quantitatively accounted for by the 2-state Monod, Wyman, and Changeux model (59).   
There are two X-ray crystal structures of EcPFK that have been published.  The first 
EcPFK structure reported was of the activator bound ternary complex (EcATC) which has 
fructose 1,6-bisphosphate (FBP) bound to the catalytic site, MgADP bound to the catalytic 
site, and MgADP bound to the allosteric site (PDB entry 1PFK) (55).  This EcATC structure 
was concluded to represent the “R-state conformer”, consistent with the hypothesis that 
EcPFK can be described by a 2-state model (55).  The second structure reported was the apo 
structure (EcApo) of the enzyme (PDB entry 2PFK) (56).  Contrary to the prediction of 
Blangy et al. (57), Evans et al. concluded that the EcApo structure, represents the “R-state 
conformer” of EcPFK.  Evans also noted that EcApo did not display the expected quaternary 
structure shift first identified by their group in 1986 (60).  The 1986 publication reported 
Bacillus stearothermophilus phosphofructokinase (BsPFK) with the analog inhibitor 2-
phosphoglycolate bound at the allosteric sites but unfortunately had a low 7Å resolution 
(PDB entry 5PFK) (60).  BsPFK, like EcPFK, is a homotetramer with four identical catalytic 
sites, four identical allosteric sites (52, 61, 62).  The monomers of BsPFK consist of 319 
residues and share a 55% amino acid sequence identity with the 320 residues of EcPFK (62).  
This isoenzyme is activated and inhibited by MgADP and PEP, respectively (52) as well. 
In 1990 Evans et al. published yet another BsPFK crystal structure.  The structure 
published was a 2.5Å resolution BsPFK structure bound to 2-phosphoglycolate (BsPG) 
depicting a high resolution “T-state conformer” (PDB entry 6PFK) (53). Evans also 
published BsPFK with F6P and MgADP bound to the catalytic site as well as MgADP to the 
allosteric site (PDB entry 4PFK), yielding the structure of the activator bound ternary 
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complex (BsATC) (52).  The series of EcPFK and BsPFK crystal structure publications by 
Evans et al., combined with the high structural similarity between the two isoenzymes, has 
lead some groups to use BsPG as a guide for EcPFK research (63-68). 
BsPFK is a completely different enzyme with a completely different set of allosteric 
and kinetic parameters.  The F6P affinity reported for BsPFK is 10 times higher than that of 
EcPFK.  Also, when considering F6P binding, EcPFK displays very strong F6P homotropic 
cooperativity while BsPFK shows very little in the presence of MgATP.  Allosteric coupling 
between F6P and PEP for BsPFK is more than 10-fold greater than EcPFK.  The van’t Hoff 
analysis of each enzyme shows that the free energy of allosteric coupling (ΔGax) for BsPFK 
is driven by the entropic (TΔSax) component while EcPFK is dominated by the enthalpic 
(ΔHax) contribution (17, 18, 69, 70).  Using the allosteric behavior displayed by BsPFK as an 
explanation of the allosteric inhibition displayed by EcPFK, is a rough approximation at best.  
The BsPG structure not only features an enzyme that is not EcPFK, but also an analog of the 
native allosteric inhibitor.  Though no kinetic data were published, 2-phosphoglycolate (PG) 
was reported to have a weak affinity for BsPFK but to yield the comparable kinetic effects to 
that of PEP (53).  Later studies showed that BsPFK affinity for PEP is 10 times stronger than 
PG and the allosteric coupling between F6P and PG is 10-fold greater (71).  In this report we 
present the crystal structure of EcPFK with PEP bound to the allosteric sites at a 2.8Å 
resolution (EcPEP).  EcPEP is the first reported EcPFK structure with any inhibitor bound.  
EcPEP is also the first known crystal structure of any wild type bacterial PFK bound to its 
physiological allosteric inhibitor (Figure 2-1). 
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Figure 2-1: Two views of the crystal structure for EcPFK with PEP bound to the 
effector site.  Peptide chains are represented as ribbon structures and PEP is 
represented as yellow surface fill structures. Left is a side view if the structure, and 
right is a top down view.
90°$
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Materials and Methods 
Enzyme Source and Purification 
Wild type E. coli PFK-1 gene, as described previously (72), was expressed from the 
pGDR148 plasmid which was transformed into competent RL257 cells (MQ ∆pfkB :: FRT 
∆pfkB:: ∆pfkA, MQ is a lac+ laqiq derivation of MC4100), a PFK-1 and PFK-2 deficient 
strain (73). Once transformed into RL257, the EcPFK producing cells were stored at -80 ºC 
in a glycerol solution consisting of 50% glycerol, 50 mM TRIS HCl pH 7.5, 5 mM MgCl2, 
and 0.1 mM EDTA.  The purification of EcPFK was purified according to the methods of 
Johnson et al. with modifications (74). The frozen cells were resuspended in 50 mL of TRIS 
Purification Buffer (50 mM Tris-HCl pH 7.5, 5 mM MgCl2 and 0.1 mM EDTA). Cells were 
lysed by sonication using a Sonic Dismembrator Model 550 (Fisher Scientific). The 
sonication protocol consisted of fifteen-second pulses followed by a one-minute rest period 
to allow the cells to cool. A total sonication time of 8 minutes was used. The crude lysate was 
clarified by centrifugation at 12,000 RPM for 60 minutes in a Beckman J2-21 centrifuge. The 
pellet was discarded.The supernatant was incubated in the presence of deoxyribonuclease I at 
37 °C for 15 minutes and then centrifuged for 60 minutes. The supernatant containing EcPFK 
was then diluted to 120 ml using Buffer A (50 mM Tris-HCl pH 7.5, 5 mM MgCl2 , 0.1 mM 
EDTA, and 100 mM NaCl). The 120 ml supernatant containing EcPFK was then loaded onto 
a column containing a 40 ml bed volume of Mimetic Blue 1 agarose resin, from Prometic 
Biosciences (Rockville, MD), equilibrated with Buffer A. The supernatant was loaded onto 
the column at a rate of 2 ml/min. After the supernatant was loaded any unbound protein 
and/debris was washed from the column using 800 to 1000 mL of Buffer A, or until the pass 
through from the column had an absorbance of approximately 0.012 at 280 nm. EcPFK was  
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then eluted using a gradient of Buffer A and Buffer B (50 mM Tris-HCl pH 7.5, 5 mM 
MgCl2 , 0.1 mM EDTA, and 2.5 M NaCl) over 200 ml. Fractions were collected in 10 ml 
increments and checked for PFK maximal activity and A280 reading. The fractions having 
enzymatic activity and low contamination were pooled together as one sample. The pooled 
sample was then dialyzed against TRIS Purification Buffer and concentrated using Amicon 
Ultra-15 (100K). The concentrated sample was then dialyzed against EPPS storage buffer (50 
mM EPPS pH 8.0, 10 mM NH4Cl, 10 mM MgCl2, and 0.1 mM EDTA). SDS-PAGE was 
performed and used to check the EcPFK purity.  Protein concentrations were determined 
using the BCA protein assay reagent (75). Absorbance readings using ε278 = 0.6 cm2mg−1 
(76) were taken and they agreed with BCA determined protein concentrations.  PEP was then 
added to the EcPFK in EPPS storage buffer, for a total concentration of 5 mM PEP and a 
final concentration of 15.7 mg/mL for EcPFK. 
Crystallization and Data Collection 
EcPFK bound to PEP was crystallized using the hanging drop vapor diffusion method 
at 16°C (77). Crystallization was achieved in a 5 μl drop consisting of 1.5 μl of buffer (0.1 M 
HEPES pH 7.5, 0.1 M spermidine, 8% v/v propanol, and 18% w/v polyethylene glycol 
8,000) and 3 μl of protein (stock concentration of EcPFK was 15.7 mg/mL with 5.1 mM 
PEP). The resulting EcPFK crystals were soaked in 30% ethylene glycol and then flash-
frozen in a liquid N2 stream at 100 K. The diffraction data were then collected on an APS 
beam line 23-ID (insertion device) using a MAR 300 CCD detector (MarMosaic from 
Marresearch-Charged Coupled Device) (Rayonix LLC, Evanston, IL). The HKL2000 
program package (HKL Research, Inc., Charlottesville, VA) (78) was used for integration 
and scaling. 
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Structure Determination and Refinement 
The structure of EcPEP was solved by molecular replacement using the program 
Phaser (University of Cambridge, Department of Haematology, Cambridge Institute for 
Medical Research, Cambridge, England) (79), as part of the X-ray crystallography software 
suite CCP4 (STFC Daresbury Laboratory, Daresbury, Warrington, England) (80). The 
products bound crystal structure of EcPFK (1PFK) (55) was used as the model for molecular 
replacement. PHENIX (Lawrence Berkeley National Laboratory, Berkeley, CA) (81) was 
used for rigid body refinement of the structure. Manual modifications and fittings were 
performed using COOT (York Structural Biology Laboratory, University of York, 
Heslington, York, England) (82). After each manual refinement using COOT, the structure 
was again refined by PHENIX until the R-factors converged. The stereochemical quality of 
the final EcPFK model was verified by MolProbity (Department of Biochemistry, Duke 
University, Durham, NC) (83).   
 Data collection and refinement statistics for the crystal structure of PEP bound EcPFK are 
found in table 2-1. 
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Table 2-1: Data Collection and Refinement Statistics for PEP bound EcPFK 
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Figure 2-2: Representation of the four homo tetramers of EcPFK.  Each monomer is 
represented by a different color and a different letter.  The allosteric sites, yellow 
octagons, are located on the yz-plane and the catalytic sites, orange squares, are located 
on the xy-plane. 
 
 
 
Table 2-2: The RMSD values between the alpha carbons of each of the PEP bound 
EcPFK subunits.  These values were calculated using UCSF Chimera (84). 
Y
X
Z
Table 2-2:!
Subunit! B! C! D!
A! 0.58 Å! 0.37 Å! 0.59 Å!
B! 0.58 Å! 0.43 Å!
C! 0.62 Å!
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Results and Discussion 
General Structure 
The asymmetric unit of EcPEP consists of four subunits that form the native 
homotetramer.  The four allosteric sites lie on the interface residing along the yz-plane while 
the four catalytic sites lie at the interface along the xy-plane (Figure 2-2). Since EcPFK and 
BsPFK are both homotetramers, they can each be described as a dimer of dimers.  The 
dimers will be designated as dimers AB and CD when dividing the tetramer along the xy-
plane (Figure 2-2).  EcPEP has a space group of p 1 21 1 and a final resolution of 2.8Å.  
There are a total of 320 residues represented in this structure.  EcPEP has a total of 203 water 
molecules.  There are four PEP molecules identified in EcPEP, one bound to each of the four 
allosteric sites.  The four monomers in the structure differ slightly from each other as 
evidenced by root-mean-square deviation (RMSD) values between the aligned alpha carbons 
ranging from 0.37Å to 0.62Å (see Table 2-2 for all RMSD values).  Monomers A and C have 
an RMSD of 0.37Å.  Monomers B and D have an RMSD of 0.43Å (Table 2-2).  The b-
factors for the individual monomers also show small variance but remain quite similar 
(Figure 2-3). Given the small variances throughout the structure all further results and 
discussion will be in reference to monomer C unless noted otherwise. 
The overall structure of EcPEP is similar to BsPG but more similar to the two 
previously reported EcPFK structures (53, 55, 56).  When superimposed, the alpha carbons 
of EcPEP and BsPG give an RMSD value of 0.80Å.   
 36 
 
 
 
 
Figure 2-3: Comparison of B-factors between the individual monomers of PEP bound 
EcPFK.  The monomers are designated A, B, C, and D.
A B!
DC
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When EcPEP is superimposed with EcApo and EcATC the RMSD values are 0.64Å and 
0.72Å, respectively (Table 2-3).  The larger RMSD value between EcPEP and BsPG is not 
surprising since the two proteins only share a 55% amino acid sequence identity. The RMSD 
values are based on the alignment of the alpha carbons between two proteins and therefore 
inherently related to the extent of sequence identity.  These RMSD values further emphasize 
the fact the EcPFK and BsPFK are distinct proteins and should not be viewed as 
interchangeable.  The remainder this section will focus on the comparison between EcPEP, 
EcApo, EcATC, and BsPG.  Even though BsPG is a different protein, there is value in 
highlighting the differences between the two inhibitor bound structures, EcPFK and BsPG. 
Subunit Interfaces 
EcPEP displays a quaternary rotation between dimers AB and CD, about the z-axis, 
similar to that seen in BsPG but to a lesser degree (53).  UCSF Chimera was used to measure 
the quaternary rotation (84).  First the designated AB dimers of the EcPEP structure and a 
reference EcPFK structure, are superimposed while allowing the CD dimers to be excluded 
from the calculation.  Second, in a separate step the CD dimers are aligned while allowing 
the AB dimers to rotate freely.  Once the CD dimers are aligned the “measure rotation” 
command is used, with respect to EcPEP in this example, to display the degree of rotation 
required to align the CD dimers from the resting position where the AB dimers are aligned.  
For a comparison, the BsPG quaternary rotation relative to BsATC, reported by Evans et al. 
as 7° (53), was measured utilizing UCSF Chimera and yields a value of 6.9°.  Using EcApo 
as the reference for the relative positions of the AB and CD dimers, we assessed the rotation 
of both EcPEP and EcATC.  The rotation for EcPEP relative to EcApo is +2.9°.  The rotation 
about the z-axis for EcATC relative to EcApo is -2.0° (Table 2-4).  This finding suggests that  
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Table 2-3: RMSD values between the crystal structure of the PEP bound EcPFK and 
the ADP bound structure of EcPFK, the apo structure of EcPFK, and the PG bound 
structure of BsPFK. 
 
 
 
 
Table 2-4: The degree of quaternary structure rotation, between the AB and CD 
dimers, about the z-axis for EcPFK and BsPFK. BsApo is the apo BsPFK structure, 
PDB entry 3U39. 
 
 
Table 2-3:!
Structures Compared! RMSD value (Å)!
EcPEP − EcApo! 0.64!
EcPEP − EcADP! 0.72!
EcPEP − BsPG! 0.80!
Table 2-4:!
Structures! Rotation ! Structures! Rotation!
EcPEP vs. EcATC! 4.8°±0.1°! BsPG  vs. BsATC! 6.9°±0.1°!
EcPEP vs. EcApo! 2.9°±0.1°! BsPG  vs. BsApo! 5.8°±0.1°!
EcApo vs. EcATC! 2.0°±0.1°! BsApo vs. BsATC! 1.2°±0.1°!
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EcApo does indeed reflect a unique conformation, contrary to the conclusion by Evans et al. 
(56).   
The quaternary rotation of BsPG has been attributed to the higher ratio of subunit 
interface area between individual subunits within the AB/CD dimers along the yz-plane 
(intra-dimers) versus the subunit interface area across within the AD/BC dimers (inter-
dimers) along the xy-plane (53).  BsPG shows a intra to inter-dimer interface ratio of 1:0.58 
(intra:inter).  EcPEP also has an intra to inter-dimer interface ratio of 1:0.58.  However, 
BsApo and EcApo have intra to inter-dimer contact ratios of 1:0.61 and 0.83:1, respectively,  
(Table 2-5). The data in Table 2-5, shows that EcPEP has an increased intra-dimer subunit 
interface area of nearly 2-fold and decreased its inter-dimer subunit interfaces by almost 12% 
with respect to EcApo.  
BsPG shows a relatively moderate 14% intra-dimer and 9% inter-dimer subunit 
interface change compared to BsApo.  EcATC has an intra to inter-dimer interface ratio of 
1:0.74.  Relative to EcApo, EcATC displays an increase in its intra-dimer subunit interface 
area by almost 2.3-fold and a 1.4-fold increase in its inter-dimer subunit interfaces.  The 
subunit interface comparison shows that PEP has a larger impact on EcPFK than PG has on 
BsPFK.  This finding is somewhat contradictory since EcPEP displays a smaller quaternary 
structure rotation than the BsPG structure.  The data do not indicate whether the difference in 
the relationship between the change in monomer contact and quaternary structure rotation is 
a result of different allosteric ligands, different proteins, or a combination thereof. 
For each monomer subunit, β-strand I (β-I) lies at the xy-interface.  BsPG shows β-I 
for each subunit has moved closer to the interface and form two new hydrogen bonds with 
the neighboring β-I, relative to the other BsPFK structures (53). 
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Table 2-5: Intra and inter dimer subunit contact area ratios.  The contact area between 
dimers is given for apo, MgADP bound, and PEP bound structures of EcPFK.  The 
data for apo, MgADP bound, and PG bound BsPFK is listed for comparison.
Table 5:!
Structure! Intra or Inter!
Contact 
Area (Å2)!
Ratio!
(xy:yz)! Structure!
Intra or 
Inter!
Contact 
Area (Å2)!
Ratio!
(xy:yz)!
EcPEP! intra! 1950! 1 : 0.58! BsPG! intra! 2300! 1 : 0.58!inter! 1140! inter! 1330!
EcApo! intra! 1070! 0.83 : 1! BsApo! intra! 2010! 1 : 0.61!inter! 1290! inter! 1220!
EcATC! intra! 2450! 1 : 0.74! BsATC! intra! 1260! 0.59 : 1!inter! 1820! inter! 2130!
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In BsPG, Thr245 of β-I forms a hydrogen bond with the main chain of the neighboring 
subunit’s β-I.  EcPEP does not show any hydrogen bonding between the neighboring β-I.  
Also, the EcPEP structure does not provide evidence of a notable decrease in distance 
between the two β-I at the xy-interface.  It should also be noted that no hydrogen bonding or 
significant changes in distance occur between neighboring β-I for EcApo and EcATC as well 
(Figure 2-4).  This lack of β-I interaction suggests that EcPFK does not propagate the same 
structural changes as BsPFK. 
Another interface characteristic across the xy-plane is the 6-F loop interacting with 
T70 in BsPG.  Here A157 and S159 of the 6-F loop are seen interacting with T70 across the 
interface (53).  In EcPFK all three of these positions are serine residues.  In the EcPEP 
structure , S157 and S70 are not interacting with any residues across the xy-interface.  S159 is 
primarily seen hydrogen bonding with D12 (159(OHγ)-12(Oδ)) and T66 (159(OHγ)-66(O)) across 
the subunit interface.  The positions of D12 and T66 allow S157 and S159 to maintain their 
contributions to the helical structure of the carboxy terminal end of α-helix 6 (Figure 2-5).  
The structural implications of α-helix 6 are further discussed later with the effector binding 
site.  For both EcATC and EcApo, S157 does not interact across the xy-interface while S70 is 
shown hydrogen bonding with S159 of the neighboring monomer.  EcATC and EcApo also 
possess the same D12 and T66 interaction displayed by EcPEP. 
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Figure 2-4: The figures above show the positioning of beta strand I from neighboring 
monomers across the xy-interface in EcPEP (purple) aligned with BsPG (dark blue) in 
box A, EcADP (yellow) in box B, and EcApo (cyan) in box C. 
 
 
 
 
 
Figure 2-5: The figures above show the positioning of 6-F loop in EcPEP (purple) 
aligned with BsPG (dark blue) in box A, EcATC (yellow) in box B, and EcApo (cyan) in 
box C. 
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A
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Active Site 
The BsPG active site was noted by Evans et al. to only have a few changes to the 
ATP binding site relative to BsATC (12).  The R72 side chain forms a salt bridge with E241 
across the yz-interface, which could potentially leave R72 unavailable for ATP binding 
interactions (53).  In EcATC the R72 side chain was reported to be interacting with both the 
products FBP and ADP (55).  EcPEP does not show or imply the R72 side chain to be 
involved in any type of protein interactions.  R72 is instead directed towards the solvent.  
Although the EcApo structure does not have the complete coordinates for the side chain of 
R72, the backbone and side chain atoms through the γ carbon appear to have adopted a 
similar position to that of R72 in EcPEP. 
A characteristic of BsPG noted by Evans et al. to be critical to BsPFK inhibition is 
the shift in position of R162 in the F6P binding site with E161 upon the binding of PG (12).  
The position of E161 in BsPG now allows it to form a salt bridge with R243.  E161 is 
thought to effectively limit the availability of both R243 and R162 which are both important 
F6P binding residues (53).  The role of E161 in the mechanism of allosteric inhibition for 
BsPFK was shown to be minor, at best, by Reinhart et al. (70).  EcPFK has an asparagine 
residue at position 161 and not a glutamate.  N161 is positioned in the F6P binding site for 
EcPEP, but would not have the same potential effect of a glutamate at the same position (67).  
N161, in both EcATC and EcApo, is also shown to adopt an extremely similar conformation 
to that seen in the EcPEP crystal structure.  EcPEP does however show R162 to be 
interacting with the side chain of E241.  This interaction is not likely to have a great impact 
on PEP bound EcPFK since the same interaction also appears in both EcApo and EcATC.  
R243 along with R252 and E222 were concluded by Evans et al. to be positioned in BsPG so  
 44 
 
 
 
Figure 2-6:  Figure showing the electron density map for PEP bound to wild type E. coli 
PFK in the EcPEP structure reported in this dissertation.  Yellow represents carbon, 
red represents oxygen, and white represents phosphorus. 
 
 
Figure 2-7a: The overlay of the allosteric effector binding site from EcPEP (purple) 
aligned with EcApo (cyan).  PEP is shown in green.
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that they would clash with F6P when it approached for binding.  The same three residues 
have adopted very similar positions and conformations in EcPEP, although this is once again 
the case for all three known EcPFK structures.  R243, like the aforementioned R72, does not 
appear to be involved in any notable interactions that could shed light on PEP inhibition. 
Allosteric Site: 
Figure 2-6 shows the crystal structure with PEP bound to the effector site of EcPFK 
along with an overlay of the electron density map.  This overlay clearly indicates that ligand 
bound to effector binding site is PEP.  The allosteric binding site binds with PEP using 4 
residues from one subunit, R21, R25, R54, S58 and two residues from the adjacent subunit 
across the yz-interface, R154 and K214.  The phosphate of PEP is directed deep into the 
binding site and being coordinated by the side chains of residues R21, R25, and R154 (Figure 
2-7a).  R54 and K214 interact with the carboxylic group oxygens in PEP.  S58 appears to 
interact with the bridging oxygen of PEP.  BsPG shows a similar interactions with R21, R25, 
R154, and K214 (Figure 2-7b).  BsPG differs, however, in that it does not show comparable 
interactions with residues at the 54 and 58 positions, which are valine and glycine, 
respectively.  Instead, BsPG displays R211 interacting with the carboxyl oxygens, while R25 
appears to help coordinate the bridging oxygen (53).  The EcATC structure shows MgADP 
interacting with all of the same residues that coordinate PEP with a few additional residues 
(Figure 2-7C).  MgADP is also oriented so that the phosphates are directed towards the 
interior of the enzyme and the adenine moiety is still on the surface of the enzyme.  R21, 
R25, R154, R54, and S58 are all seen interacting with the phosphate oxygens and K214 
interact with the hydroxyls of the adenosine moiety.  MgADP additionally binds with Y55,  
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Figure 2-7b: The overlay of the allosteric effector binding site from EcPEP (purple) 
aligned with BsPG (dark blue).  PEP is shown in green and PG is shown in orange. 
 
 
Figure 2-7c: The overlay of the allosteric effector binding site from EcPEP (purple) 
aligned with EcATC (yellow).  PEP is shown in green and ADP is shown in red. 
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D59, and S158.  D59 and S158 interact with the hydroxyls of the adenosine moiety while 
Y55 is thought to base stack with the adenine moiety at the surface of the enzyme.   
EcPEP appears to close the allosteric binding site around the PEP molecule.  To 
further characterize allosteric site closure we obtained surface model calculations from the 
CASTp server (85) and viewed them in UCSF Chimera (84).  Upon examining the CASTp 
data it is evident that three of the four allosteric sites completely enclose PEP.  The fourth 
allosteric site is completely enclosed except for a small mouth, open towards the solvent, 
with a calculated molecular surface area of approximately 9.1Å2.  This same type of analysis 
shows a similar closure of BsPGs allosteric sites, although not a complete closure leaving PG 
access to solvent.  Each allosteric binding site has at least 1 mouth with molecular surface 
areas averaging approximately 25Å2 (Table 2-6). 
The closure of BsPGs allosteric sites was concluded to arise from the movement of 
the c-terminal end of α-helix 6 (α-6).  α-6 in BsPG loses the helical contributions of residues 
157-160 which become part of loop 6-F.  The loss of structure to α-6 and lengthening of loop 
6-F allows β-strand F (β-F) to shift its position towards the allosteric binding pocket.  β-F is 
hydrogen bonded to β-strand H (β-H) causing β-H to also shift towards the allosteric binding 
pocket.  Finally, loop 8-H hinges at G212 and S216 pushing α-helix 8 (α-8) towards the 
allosteric binding site(53).  The loop 8-H residues K211 and H215 make hydrogen bonds 
across the subunit interface with Y55 and D59, respectively.  α-6 in EcPEP does appear tilted 
at its carboxy-terminal end, relative to EcATC and EcApo, but does not lose its helical 
conformation.  The closure of the allosteric sites indicates once again that the protein and 
allosteric event captured in the structures of EcPEP and BsPG are very different.  The data  
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Table 2-6: The allosteric pocket formation data using CASTp analysis (85).  For 
EcPEP, the first subunit listed in each subunit pair (A-B, etc..) contributes residues 21, 
25, 54, 55, 57, 58, and 61. The second subunit contributes residues 154, 185, 212, 213, 
214, 215, and 319.  For BsPG the first listed subunit contributes residues 21, 25, 57, 58, 
59, 61, and 62.  The second subunit contributes 154, 184, 185, 187, 211, 212, 213, 214, 
215, 216, 217, and 319. 
Table 2-6:!
Structure 
(Dimer Pair)! Volume (Å
3)! Pocket Area (Å2)!
# of 
mouths!
Avg Mouth 
Area (Å2)!
Avg Mouth 
Circumference (Å)!
EcPEP (A-B)! 163.8! 166.5! 1! 9.1! 10.9!
EcPEP (B-A)! 150.4! 166.8! 0! N/A! N/A!
EcPEP (C-D)! 227.1! 231.4! 0! N/A! N/A!
EcPEP (D-C)! 192.8! 215.3! 0! N/A! N/A!
BsPG (A-B)! 260.5! 235.2! 1! 19.0! 17.2!
BsPG (B-A)! 283.9! 258.9! 1! 18.7! 16.3!
BsPG (C-D)! 422.3! 329.2! 2! 30.9! 22.7!
BsPG (D-C)! 354.4! 299.6! 2! 25.3! 19.3!
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Figure 2-8: The figures above show the interactions between β-strands F and H in 
EcPEP (purple) aligned with BsPG (dark blue) in box A, EcATC (yellow) in box B, and 
EcApo (cyan) in box C. Hydrogen bonds for EcPEP are represented in purple and 
hydrogen bonds for BsPG, EcATC, and EcApo are all represented in black. 
 
  
α-6"
β-F"
β-H"
α-8"
α-6"
β-F"
β-H"
α-8"
α-6"
β-F"
β-H"
α-8"
CB"A
 50 
 
presented here cannot distinguish between the contributions of ligand or protein, but they do 
serve to highlight that the binding of PG to BsPFK and the binding of PEP to EcPFK each 
produce unique interactions.  Instead of loop 6-F stretching, the most amino terminal 
hydrogen bond between β strand F (β-F) and β strand H (β-H) in the EcATC and EcApo 
structures is lost, A216(N)-R162(O) (Figure 2-8).  The result is unzipping of the amino-
terminal end of these central strands of the parallel β-sheet GFHI.  The separation of β-F and 
β-H allows the carboxy-terminal end of α-6 to predominantly maintain its helical structure 
and for α-8 to shift towards the allosteric binding site.  This action leaves α-6 and β-F 
relatively unmoved compared to EcApo and EcADP.  The unzipping is stabilized by the 
hydrogen bond formation between the side chains of K213 and E187, within the same 
monomer.  K213 appears to stabilizing a-13 helix, via E187 interaction, in the EcATC 
structure.  K213 side chain interactions are unclear in EcApo since its side chain is 
unresolved.  For both EcATC and EcApo, the E187 side chain is also hydrogen bonding with 
I217.  EcApo shows an additional interaction between the side chains of E187 and R153. 
 
Conclusion 
The 2-state Model has been used to characterize the previously known crystal 
structures of EcPFK and BsPFK (52-56). Not only has EcATC been characterized as the R-
State enzyme but also EcApo (55, 56).  Thermodynamic linkage analysis, presented in 
chapter 1, shows that the disproportionation reaction represents a much more accurate 
depiction of the species of enzymes discussed in this dissertation.  The disproportionation 
reaction describes the equilibrium between the two binary complexes, i.e. the enzyme bound 
to substrate (EA) or allosteric effector (XE), on one side of the equilibrium and on the other 
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side is the apo enzyme (E) and the ternary complex (XEA), i.e. where both substrate and 
allosteric ligand are bound.  When accounting for the disproportionation equilibrium, the 
known crystal structures of EcPFK can be identified as a specific species and characterized 
independently of the other species.  Given the disproportionation equilibrium, EcPEP is the 
only known crystal structure of an EcPFK binary complex.  EcATC represents the activated 
ternary complex while EcApo represents the unbound enzyme. 
In this chapter we have shown that BsPG is, structurally, very different from EcPEP.  
The differences between BsPG and EcPEP should not be a surprise since BsPFK and EcPFK 
are different proteins.  Though these two bacterial PFKs share 55% amino acid identity, they 
also have markedly different kinetics and thermodynamic parameters (17, 62, 69, 71).  The 
differences BsPG and EcPEP are largely due to the difference in amino acid sequences, but it 
should not be forgotten that PG is an analog of the natural allosteric inhibitor for both 
enzymes.   
Thermodynamic linkage analysis provides for the identification of another difference 
between EcPFK and BsPFK, the component contributions of ΔGax.  Since Qax is an 
equilibrium constant, we can use it to calculate the free energy of the coupling between A 
and X.  For allosteric inhibition, Qax is less than 1 and is ΔGax positive.  Allosteric activation 
yields a Qax value greater than 1 and a negative ΔGax.  By examining the temperature 
dependencies of coupling for BsPFK and EcPFK in van’t Hoff analyses, equation 2-1 can be 
utilized to determine the enthalpic and entropic contributions to ΔGax (Equation 2-1) (86).   
When ΔH and ΔS have the same sign, equation 2-1 states that ΔHax and TΔSax oppose 
one another. If ΔGax retains the sign of ΔHax then it is enthalpically dominated.   Oppositely, 
when ΔGax retains the sign of TΔSax then ΔGax is entropically dominated.    
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Equation 2-1: This equation describes the relationship between free energy of coupling 
(Gax), the enthalpy of coupling (Hax), the entropy of coupling (Sax), and the coupling 
quotient (Qax) (86). Note that ΔGax is a standard state free energy (ΔG°) and that we 
have deviated from the standard notation. 
 
When previously studied, ΔGax for EcPFK was shown to be enthalpically (ΔHax) dominated 
with respect to both allosteric ligands, MgADP and PEP (18, 69).  The same type of study 
has shown that BsPFK is dominated by its entropic component (TΔSax) for both allosteric 
ligands (17, 70).  When considering the thermodynamic origins of allosteric coupling along 
with all of the data presented in this publication, the use of BsPG as a substitute structure for 
EcPEP is fundamentally wrong. To properly investigate the allosteric coupling of EcPFK or 
BsPFK, all of the enzymatic states represented in the disproportionation equilibrium must be 
considered. In this publication we reported the crystal structure of EcPEP. The EcPEP 
structure represents the inhibitor bound binary complex of EcPFK and is not a representation 
of the allosteric coupling between F6P and PEP. The structure of the ternary complex of 
EcPFK, PEP, and F6P is still needed in order to have a physical representation of the 
allosteric coupling between F6P and PEP. 
∆Gax = -RTlnQax = ∆Hax - T∆Sax"
"
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3. ANALOGS AND MUTANTS  
 
 
 
Introduction 
Phosphofructokinase from Escherichia coli (EcPFK) is catalytically active as a 
homotetramer with each monomer comprised of 320 amino acids.  The tetramer is 
approximately 34kDa in size and has four identical catalytic sites and four identical allosteric 
sites.  The four allosteric sites lie on the interface residing along the yz-plane while the four 
catalytic sites lie at the interface along the xy-plane (Chapter 2, Figure 2-2).  EcPFK 
catalyzes a phosphoryl transfer from ATP to convert fructose-6-phosphate (F6P) into 
fructose-1,6-bisphosphate (FBP).  EcPFK is inhibited by the glycolytic product phospho-
enol-pyruvate (PEP) and activated by its catalytic product MgADP.  Both PEP and MgADP 
result in K-type effects only and, more importantly to the current study, bind to the exact 
same allosteric site.  Not only do the two allosteric effectors use the same site but, as 
disclosed in chapter 2, PEP clearly utilizes many of the same residues for binding as 
MgADP.  This phenomenon is of great interest due to the fact that the two very different 
ligands cause markedly different behaviors by EcPFK.  PEP causes the Kia for F6P to 
increase over 100-fold over the uninhibited value, while MgADP causes the F6P Kia to 
decrease to less than 1/10 the unaffected value.  How is EcPFK able to differentiate between 
two ligands that bind to the same binding site? 
Previous studies have proposed the two state model to explain the behavior of 
EcPFK.  The two state model simply suggests that EcPFK exists in an equilibrium between 
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activated and inhibited conformations of the enzyme.  Further, the two state model states that 
the equilibrium is altered when an allosteric ligand binds to EcPFK, causing the enzyme to 
favor a particular state depending on the ligand.  When using the two state model to explain 
how EcPFK is able to differentiate between allosteric ligands, the need arises for the 
identification of the “triggers” for such transitions.  The first structure suggested to embody, 
at least in part, a component of the two state model came in the form of activator bound 
ternary complex of EcPFK (EcATC) (55).  EcATC possesses the products, fructose-1,6-bis-
phosphate (FBP) and MgADP, bound to the catalytic site and MgADP bound to the allosteric 
site. 
With the first crystal structure of EcATC published, the residues seen interacting with 
MgADP in the allosteric site became the focus of mutation studies (55, 87).  Fersht et al.  
performed kinetic studies on EcPFK allosteric site mutations in the presence of PEP and 
MgGDP, individually.  In this allosteric site study, the group concluded that E187 was 
critical to the control of the equilibrium between the “R” and “T” states.  The mutation 
E187A was reported to cause a reversal of roles for the two allosteric effectors, i.e.  MgGDP 
becomes an inhibitor and PEP an activator (87).  Effectively, E187 appeared to be the residue 
controlling the switch between “R” and “T” states.  However when this mutation was studied 
utilizing thermodynamic linkage analysis, it was shown that MgADP and PEP had not 
switched allosteric roles.  Reinhart et al.  determined that E187A merely abolishes the 
allosteric response elicited by MgADP and, like wild type, displays product inhibition caused 
by excess MgADP (88).  In another report Reinhart et al. showed that the observed activation 
of F6P binding, by PEP, is a MgATP dependent phenomenon which only occurs at MgATP 
concentrations above 25 µM (89).  The MgATP dependent phenomenon described by 
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Reinhart et al. is in agreement with previous investigations performed on wild type EcPFK 
(18, 74, 90).  Thermodynamic linkage analysis allowed Reinhart et al. to determine that E187 
does not have a large impact on the nature of the allosteric effect but is rather a residue that is 
critical to the magnitude of said effect.   
When examining the ability of EcPFK to differentiate between MgADP and PEP, the 
obvious focus is the interaction between allosteric ligand and the residues in the enzyme’s 
binding site.  In comparing the two native allosteric ligands a large difference between them 
is their size (Figure 3-1).  MgADP is a much larger molecule having a molecular formula of 
Mg2+C10H15N5O10P2 and a molecular weight of 427.2.  PEP has a molecular formula of 
C3H5O6P and a molecular weight of 168.0.  MgADP has many functional groups, including 
the moieties of adenine, ribose, and pyrophosphate.  PEP is a much simpler compound 
comprised of a central carbon that is bonded to three functional groups.  The three groups are 
a phosphate, methylene, and carboxyl.  Even with such a large discrepancy in size PEP and 
MgADP bind in much the same manner.  Reported in chapter 2, the EcPFK crystal structure 
with PEP bound to the allosteric site (EcPEP) shows PEP bound deep in the allosteric site.  
The phosphate of PEP is directed towards the interior of the enzyme with the bridging 
oxygen (the oxygen connecting the phosphate to the 3 carbon chain) coordinated by S58.  
The remaining phosphate oxygens are coordinated by residues R21, R25, and R154 (Chapter 
2 Figure 2-7c).  The carboxyl group is seen interacting with R54 and K214.  Analysis of the 
EcATC structure shows MgADP interacting with all of the same residues that coordinate 
PEP plus a few  
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Figure 3-1: The structure of PEP (A) and MgADP (B). 
 
 
 
 
 
Equation 3-1: Equation representing the K1/2 as a function of effector concentration.   
Parameters obtained from the fitting of this equation are the coupling quotient (Qax) the 
dissociation constant for substrate in the absence of allosteric effector (Kia°) and the 
dissociation constant of allosteric effector in the absence of substrate (Kix°) (16).
_"
_"
A B!
Kix◦ + (Qax [X]) 
K1/2 =
Kia◦ (Kix◦ + [X]) 
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additional residues.  MgADP is also oriented so that the phosphates are directed towards the 
interior of the enzyme and the adenine moiety is still on the surface of the enzyme.  R21, 
R25, R154, R54, and S58 are all seen interacting with the phosphate oxygens and K214 
interacts with the hydroxyls of the adenine moiety.  MgADP additionally binds with Y55, 
D59, and S158.  D59 and S158 interact with the hydroxyls of the adenine moiety while Y55 
is thought to base stack with the adenine moiety at the surface of the enzyme (Chapter 2, 
Figure 2-7c).   
Since thermodynamic linkage analysis separately quantifies allostery and ligand 
binding, in depth studies of the allosteric ligands and allosteric binding sites can help 
determine the portions of MgADP and/or PEP that are responsible for their individual effects.  
In this chapter, I present a study of the allosteric ligands of EcPEP in order to define the roles 
of the functional groups they possess.  Comparisons of the natural allosteric ligands and their 
analogs via thermodynamic linkage analysis, allows the determination as to whether a 
specific ligand functional group is important to ligand binding, allosteric function, or both.   
As stated in chapter one, thermodynamic linkage analysis allows for the 
determination of dissociation constants for both substrate and effector in the absence (Kiao, 
Kixo, and Kiyo representing substrate, activator, and inhibitor, respectively) and saturating 
presence (Kia∞, Kix∞, and Kiy∞) of each other.  These constants are determined by measuring 
the K1/2 of the substrate F6P (A), in saturating MgATP conditions as a function of effector (X 
or Y, activator or inhibitor, respectively) or effector analog (X’ or Y’) concentration.  By 
plotting K1/2 versus [Y] or [Y’], and fitting to equation (Equation 3-1), the parameters Kiao, 
Kiyo, and Qay can be obtained (16).  The free energy of coupling (ΔGay) between the substrate 
and effector is then calculated from the Qay value (Chapter 1, Equation 1-1).  ΔGay is positive 
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for inhibition, negative for activation, and equal to zero when no allosteric coupling is 
detected.  The dissociation constant of substrate in the absence of allosteric ligand, Kiao, the 
dissociation constant of allosteric ligand in the absence of substrate, Kiyo, and the nature and 
magnitude of the allosteric event, ΔGay, are all three critical to the assignment of roles to the 
ligand functional groups.  More specifically, the comparison of these parameters between the 
native allosteric ligand and a ligand analog allows for molecular difference to be associated 
with a change in binding, allosteric communication, neither, or both.  When the Kiyo of an 
analog effector changes and the ΔGay does not, relative to the native ligand, the molecular 
difference is important for ligand binding.  In the opposite scenario where only ΔGay is 
affected then the molecular difference is important to allostery.  Lastly, in a third scenario 
where both Kiyo and ΔGay are affected then the molecular difference is important to both 
binding and allostery.   
An appropriate follow up to the ligand analog study is the use of thermodynamic 
linkage analysis to establish the roles of residues on the enzyme that complement the effector 
analogs.  Combining data obtained from the present analog study with information from x-
ray crystal structure, amino acids that are in position to interact with the functional groups 
were identified and examined.  Through mutations I attempted to cause EcPFK to exhibit an 
altered behavior in binding and/or allosteric activity that is comparable to what is seen with 
the wild type enzyme and the corresponding effector ligand analog.  Such a correlation 
would indeed lend further credence as to the role of ligand functional groups.  The ability to 
replicate analog behavior in mutants would also identify regions of the enzyme that are 
important in allosteric propagation and binding. 
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Materials and Methods 
All chemical reagents used in buffers for protein purifications, enzymatic assays, and 
protein crystal development were of analytical grade and purchased from Fisher-Scientific 
(Hampton, NH), Sigma-Aldrich (St. Louis, MO), Hampton Research (Aliso Viejo, CA), RPI 
(Natick, MA), MP Biomedicals (Solon, OH). Lyophilized creatine kinase, deoxyribonuclease 
I, and ammonium sulfate suspensions of aldolase, triosephosphate isomerase, and glycerol-3-
phosphate dehydrogenase were purchased from Roche Applied Science (Indianapolis, IN) 
and Sigma-Aldrich Sigma-Aldrich (St. Louis, MO). All enzymes, except creatine kinase and 
deoxyribonuclease I, were dialyzed against buffer containing 50 mM EPPS pH 8.0, 10 mM 
NH4Cl, 10mM MgCl2, and 0.1 mM EDTA before use. Creatine phosphate, F6P, and PEP 
were purchased from Sigma-Aldrich. ATP and ADP were obtained from Roche Applied 
Sciences and/or Sigma-Aldrich. NADH was purchased from RPI. All of the various effector 
analogs, with the exception of 2-phosphonomethylacrylic acid (PMAA), were purchased 
from MP Biomedicals and Sigma-Aldrich. PMAA was provided and synthesized by the lab 
of Dr. Frank M. Raushel, department of chemistry at Texas A&M University (College 
Station, TX). 
Mutagenesis 
The plasmid pGDR148 containing the wild type E. coli PFK-1 gene, as described 
previously (72), was used as the starting plasmid for the EcPFK variants created. Site-
directed mutagenesis was performed using QuickChange Site-Directed Mutagenesis System 
from Stratagene (La Jolla, CA). Oligonucleotides were synthesized by Integrated DNA 
Technologies Inc (Coralville, IA). DNA modifying enzymes were purchased from Promega 
and New England Biolabs (Ipswich, MA). Qiagen (Hilden, Germany) products were used for 
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plasmid purifications. XL1Blue cells were obtained from Promega and Stratagene. Two 
complementary oligonucleotides were used to produce the genes for each of the EcPFK 
mutants. The template oligonucleotide for each of the pairs of complementary 
oligonucleotides is shown below. The underlined bases designate the codon for the alternate 
amino acid that replaced the specific residue indicated. 
S58A: GACCGTTACAGCGTGGCGGACATGATCAACCGT 
S58C: GACCGTTACAGCGTGTGTGACATGATCAACCGT 
S58D: CTAGACCGTTACAGCGTGGATGACATGATCAACCGT 
S58N: CTAGACCGTTACAGCGTGAATGACATGATCAACCGTGGC 
S58K: CAGCTAGACCGTTACAGCGTGAAAGACATGATCAACCGTGGC 
The resulting sequences were verified via DNA sequencing at the Gene Technology 
Laboratory at Texas A&M University. 
Wild-type EcPFK and all of the mutant proteins were expressed from the pGDR148 
plasmid which was transformed into competent RL257 cells (MQ ∆pfkB :: FRT ∆pfkB:: 
∆pfkA, MQ is a lac+ laqiq derivation of MC4100), a PFK-1 and PFK-2 deficient strain (73). 
Once transformed into RL257, the EcPFK producing cells were stored at -80 ºC in a glycerol 
solution consisting of 50% glycerol, 50 mM TRIS HCl pH 7.5, 5 mM MgCl2, and 0.1 mM 
EDTA.  
Protein Expression and Purification 
LB agar plates containing 0.02 mg/ml chloramphenicol were streaked using the 
appropriate glycerol stock, and grown for 12 hours at 37 ºC. Isolated colonies were then used 
to inoculate cultures comprising 5 ml of LB and 0.02 mg/ml chloramphenicol and were 
allowed to grow over night at 37 ºC. Next, Fernbach flasks containing 1.5 L of LB media and 
 61 
 
0.02 mg/ml of chloramphenicol were inoculated with 1.5 ml of the overnight culture. The 1.5 
L cultures where grown while agitating at 37 ºC for approximately 3 hours, or until the 
culture reached an OD600 of 0.6. The 1.5 L culture was then induced with 2 mM Isopropyl 
β-D-1-thiogalactopyranoside (IPTG). Once induced the 1.5 L culture was allowed to grow 
for an additional 5 hours, or until the culture reaches an OD600 of 1.2. The cells of the 1.5 L 
culture were then harvested by centrifugation at 4,000 RPM using a Beckman Model J-6B 
centrifuge. The resulting cell pellet was then stored at -80 ºC. 
Wild type and variant EcPFK was purified according to the methods of Johnson et al. 
with modifications (74). The frozen cells were resuspended in 50 mL of TRIS Purification 
Buffer (50 mM Tris-HCl pH 7.5, 5 mM MgCl2 and 0.1 mM EDTA). Cells were lysed by 
sonication using a Sonic Dismembrator Model 550 (Fisher Scientific). The sonication 
protocol consisted of fifteen-second pulses followed by a one-minute rest period to allow the 
cells to cool. A total sonication time of 8 minutes was used. The crude lysate was clarified by 
centrifugation at 12,000 RPM for 60 minutes in a Beckman J2-21 centrifuge. The pellet was 
discarded.The supernatant was incubated in the presence of deoxyribonuclease I at 37 °C for 
15 minutes and then centrifuged for 60 minutes. The supernatant containing EcPFK was then 
diluted to 120 ml using Buffer A (50 mM Tris-HCl pH 7.5, 5 mM MgCl2 , 0.1 mM EDTA, 
and 100 mM NaCl). The 120 ml supernatant containing EcPFK was then loaded onto a 
column containing a 40 ml bed volume of Mimetic Blue 1 agarose resin, from Prometic 
Biosciences (Rockville, MD), equilibrated with Buffer A. The supernatant was loaded onto 
the column at a rate of 2 ml/min. After the supernatant was loaded any unbound protein 
and/debris was washed from the column using 800 to 1000 mL of Buffer A, or until the pass 
through from the column had an absorbance of approximately 0.012 at 280 nm. EcPFK was  
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Figure 3-2: Plot of the total units (calculated from maximal activity assays) versus 
absorption at 280 nm for fractions of EcPFK during the purification process. 
 
 
 
Figure 3-3: SDS-PAGE gel from purification process.  Lanes from left to right: EcPFK 
standard, final sample, crude, fraction #7, fraction #10, fraction #13, fraction #16, 
fraction #19, fraction #22.
 63 
 
then eluted using a gradient of Buffer A and Buffer B (50 mM Tris-HCl pH 7.5, 5 mM 
MgCl2 , 0.1 mM EDTA, and 2.5 M NaCl) over 200 ml. Fractions were collected in 10 ml 
increments and checked for PFK maximal activity and A280 reading (Figure 3-2). The 
fractions having enzymatic activity and low contamination were pooled together as one 
sample. The pooled sample was then dialyzed against TRIS Purification Buffer and 
concentrated using Amicon Ultra-15 (100K). The concentrated sample was then dialyzed 
against EPPS storage buffer (50 mM EPPS pH 8.0, 10 mM NH4Cl, 10 mM MgCl2, and 0.1 
mM EDTA). SDS-PAGE was performed and used to check the EcPFK purity (Figure 3-3).   
Protein concentrations were determined using the BCA protein assay reagent (75). 
Absorbance readings using ε278 = 0.6 cm2mg-1 (76) were taken and agreed with BCA 
determined protein concentrations. 
Enzymatic Assays 
Activity measurements of EcPFK, and its variants, were accomplished by coupling 
the oxidation of NADH to the reaction catalyzed by EcPFK. The oxidation of NADH was 
then monitored via its absorbance at 340 nm. The corresponding rate in the decrease of A340 
was followed and recorded.  See figure 3-4 for a detailed coupling scheme. Enzymatic assays 
were executed by adding 10 µL of approximately 1.8 µg/mL of EcPFK to 590 µL of assay 
buffer containing 50 mM EPPS-KOH, pH 8.0, 10 mM NH4Cl, 10mM MgCl2, 0.1 mM 
EDTA, 2 mM DTT, 0.2 mM NADH, 250 µg of aldolase, 50 µg of glycerol-3-phosphate 
dehydrogenase, 5 µg of triosephosphate isomerase. The decrease in A340 was then monitored 
for 4 minutes at 25 ºC. When maximal activity was determined, 3 mM ATP and 5 mM F6P 
were added to the assay cocktail. In enzyme kinetic experiments measuring the allosteric  
coupling between F6P and either PEP or MgADP, the concentration of all three  
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Figure 3-4: A scheme representing the enzyme coupling system used for the assay 
EcPFK activity.  Aldoase, Triosephosphate Isomerase, and Glycerol-3-Phosphate 
Dehydrogenase are used to couple the oxidation of NADH with the conversion of 
Fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F-1,6-BP).  Creatine Kinase, 
when added, is used for ATP regeneration.
EcPFK!
F6P!
MgATP! MgADP!
Creatine!
 Kinase!
Creatine!
Phosphate!Creatine!
F-1,6-BP!
Aldolase!
Dihydroxyacetone Phosphate!
Glyceraldehyde-3-phosphate!
Triosephosphate!
Isomerase!
Glycerol-3-Phosphate 
Dehydrogenase!
Glycerol-3-Phosphate!
NAD+!
NADH!
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of these ligands are varied correspondingly.  Additionally, when measuring the allosteric 
coupling between F6P and PEP, an MgATP regeneration system is utilized to prevent 
product inhibition. The MgATP regeneration system was added to the assay cocktail and 
includes 40 mg/mL creatine kinase and 4 mM phosphocreatine (Figure 3-4). MgADP, being 
both a reaction product and the allosteric activator of EcPFK, can also compete with PEP for 
binding at the allosteric sites. When measuring the allosteric coupling between MgADP and 
F6P, the various additions made of MgADP were added in tandem with equal concentrations 
MgATP. The equal addition of MgATP helps to negate the product inhibition between 
MgATP and MgADP in the active site of EcPFK (18). The MgADP contamination in the 
MgATP stock solution was quantified and accounted for all of the MgADP coupling 
measurements. All activity measurements were performed on Beckman Series 600 
spectrophotometers using linear regression to convert the change in absorbance at 340 nm 
into enzyme activity. One unit (U) of activity is defined as the amount of EcPFK needed to 
produce 1µmol of fructose 1,6-bisphosphate per minute.  
Data Analysis 
Allosteric response was determined using thermodynamic linkage analysis (16) and applying 
a single-substrate-single-effector kinetic scheme (discussed in Chapter 1, Figure 1-1). The 
scheme used assumes that substrate (A) and effector (X) bind at two separate and distinct 
binding sites on the enzyme (E). The scheme provides for two distinct dissociation constants 
for each ligand, A or X, found in the absence, Kia° and Kix°, and in the saturating presence, 
Kia∞ and Kix∞, of the other (16). The scheme shows the dependence of Kia on [X] (Figure 3-
5).  
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Figure 3-5: Plot of substrate log K1/2 versus the concentration of activator [X] and 
inhibitor [Y].  The dissociation of a substrate in the absence and saturating presence of 
effector is represented by the horizontal dashed lines.  The vertical dashed lines 
represent the dissociation constant for the effector in the absence and saturating 
presence of substrate (18). 
 
 
 
Equation 3-2: Equation to fit velocity as a function of substrate concentration. V 
represents initial velocity, Vmax is maximum velocity, [A] is the concentration of 
substrate, nH is the Hill coefficient, and K1/2 is the concentration of substrate that results 
in half the maximal velocity. 
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Equation 3-3: Competitive inhibition equation for determining the binding constant of 
an allosteric ligand analog in the absence of coupling. Kix is the apparent dissociation 
constant of the native allosteric ligand, Kix◦ is the dissociation constant of the native 
allosteric ligand in the absence of substrate and competitive allosteric ligand analog, 
[X’] is the concentration of the allosteric ligand analog, and Kix’◦ is the dissociation 
constant of the allosteric ligand analog. 
 
 
 
 
Table 3-1: Comparison of the natural inhibitor, PEP, to the inhibitor analogs that have 
been examined.  Data for PEP, PAA, CEPA, PMAA, MMA, and Pi were collected at a 
pH of 8.0 and 25°C.  Data for PG is unpublished (91) and collected at a pH of 8.0 and 
25°C.
Kix = Kix◦ 
1 + [X’] 
Kix’◦ 
Table 3-1: 
Ligand  
(mM) Qiy  
 
(kcal/mol) 
PEP 0.41 ± 0.01 0.0111  
± 0.0002 2.66 ± 0.05 
PAA 9.4 ± 0.5 0.31 ± 0.01 0.69 ± 0.02 
CEPA 55 ± 3 0.29 ± 0.01 0.73 ± 0.02 
PG 2.9 ± 0.1 0.021 ± 0.002 2.28 ± 0.22 
PMAA 15 ± 1 1 0 
MMA 50 ± 10 0.3 ± 0.1 0.7 ± 0.2 
Pi 21 ± 2 0.34 ± 0.01 0.64 ± 0.02 !
Kiy0 ΔGay
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Initial velocity rates of EcPFK were plotted as a function of F6P concentrations. The 
initial velocity data were fit to equation 3-2.  Kiao, Kiyo, and Qay were then determined by 
plotting K1/2 versus allosteric effector, and fitting to equation 3-1.  In the absence of 
observable allosteric coupling, the dissociation constant of the allosteric effector analog was 
determined by competitive inhibition with the native allosteric ligand.  When Qay is equal to 
zero, equation 3-1 is simplified to equation 3-3. 
 
Results and Discussion 
Analogs 
Previously unpublished data by Johnson et al. revealed that the Kiyo for 
phosphoglycolate (PG) is increased 10-fold relative to the Kiyo for PEP, while the change of 
ΔGay for PG is −0.38 kcal/mol from to PEP (Table 3-1, and Figure 3-6) (91).  Since the 
experiments were performed with wild type EcPFK, the allosteric and kinetic differences 
between PG and PEP are due to the differences in molecular and electronic structures 
between the two ligands.  When the molecular structures of PEP and PG are compared, the 
only difference is the absence of the methylene group in PG (Figure 3-7).  These data suggest 
that the methylene group is involved in both binding and allosteric interactions, with a larger 
impact on ligand binding. 
The next set of analogs focus on the oxygen bridging phosphate to the three carbon chain of 
PEP, as well as with the methylene group.  Phosphonoacetic acid (PPA) and 2-
carboxyethylphosphonic acid (CEPA) probe the importance of both the methylene and  
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Figure 3-6: F6P K1/2 versus [Y] or [Y’] plots.  Phospho-enol-pyruvate (PEP, red circles), 
phosphono acetic acid (PAA, blue squares), carbixyethylphosphonic acid (CEPA, green 
diamonds), methylmalonic acid (MMA, orange triangles), and inorganic phosphate (Pi, 
purple triangles) are all represented.  The lines represent the best fit to equation 3-1 for 
each allosteric ligand. 
 
 
Figure 3-7: Structures of the natural inhibitor, PEP (A), and the inhibitor analogs PG 
(B), PAA (C), CEPA (D), and PMAA (E).   
A B!
C D
E!
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bridging oxygen present in PEP.  PPA, relative to PEP, has a deletion of both the bridging 
carbon and methylene.  The deletion of the bridging oxygen not only removes a potential 
interaction, but shortens the length of the molecule (Figure 3-7).  CEPA also lacks the 
methylene group.  However, CEPA does not have a deletion of the bridging oxygen position 
but rather a substitution of carbon.  The presence of carbon at the position of the bridging 
oxygen makes the length of the molecule more similar to that of PEP (Figure 3-7).  The Kiyo 
of PPA is increased 23-fold (Kiyo=9.4 mM) relative to that of PEP (Kiyo=0.41 mM).  PPA 
also yields a large change in ΔGay (ΔΔGay) of −1.97 kcal/mol relative to PEP, a decrease 
from 2.67 kcal/mol down to 0.69 kcal/mol (Table 3-1, Figure 3-6).  The bridging oxygen 
deletion combined with the methylene deletion in PPA, resulted in substantial changes in 
binding affinity and allostery.  CEPA resulted in a Kiyo that is more than 130-fold higher 
(Kiyo =55 mM) than that of PEP and a ΔΔGay of −1.93 kcal/mol relative to PEP 
(ΔGay=0.73kcal/mol) (Table 3-1, Figure 3-6).  Replacing the bridging oxygen with carbon 
instead of deleting it appears to have further decreased ligand affinity without further impact 
on ΔGay relative to PPA.  Since there are changes to several structural variables with respect 
to PEP, we can only conclude that the disturbance of both allostery and binding, as seen in 
PPA, is predominately due to the missing functional groups and not the shortening of the 
molecules length relative to PEP. 
In order to gain more insight into the contributions of the bridging oxygen, 
phosphonomethylacrylic acid (PMAA) was examined in reference to PEP.  PMAA, relative 
to PEP, has a carbon substitution of the bridging oxygen with no other modifications.  
PMAA allows for a direct assessment of bridging oxygen to carbon substitution.  EcPFK in 
the presence of PMAA yields a Kiyo that is 36-fold larger 
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Figure 3-8: Plots of F6P K1/2 versus [PEP] at varying concentrations of 2-
phosphonomethylacrylic acid (PMAA).  F6P K1/2 at various concentrations of PEP 
with a PMAA concentration of 0 mM (red circles), 1.04 mM (blue squares), 3.25 mM 
(green diamonds), and 6.62 mM (orange triangles).  The lines represent the best fit to 
equation 3-1 for F6P K1/2 at each concentration of PMAA. 
 
 
 
Figure 3-9: Structures of the natural inhibitor, PEP (A), and the inhibitor analogs 
Methyl-Malonic Acid (B), Methyl-Succinic Acid (C), and Itaconic Acid (D). 
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−"−"
−"
−"−"
−"
 72 
 
(15mM) than PEP with no observable coupling (reference materials and methods section of 
this chapter for Kiyo calculation in the absence of coupling) (Table 3-1, Figure 3-8).  This 
suggests that the bridging oxygen is very important to both ligand binding and allosteric 
activity.  The results displayed by EcPFK in the presence of PMAA also  indicate that the 
replacement oxygen has a much larger impact on allostery.  When the PMAA result is 
considered along side the PG, PPA, and CEPA results, it is clear that the methylene group is 
primarily involved in ligand binding.  The present experiments do not completely explain 
whether it is the electronic or the steric properties of the oxygen are more important.  The 
experiments do show that PMAA, which is the most structurally similar to PEP, does not 
bind in a fashion that allows for any detectable coupling.   
Next the investigation focused on whether the phosphate on PEP is required for both 
binding and allostery, and examining the possibility that only the phosphate is required.  A 
series of small non-phosphorylated molecules were studied with wild type EcPFK.  A first 
group of compounds, which replaced the phosphate group of PEP with an additional 
carboxylate group, comprised methyl-malonic acid, methyl-succinic acid, and itaconic acid 
(Figure 3-9).  Of this group, methyl-malonic acid was the only ligand to render a detectable 
allosteric effect.  The effect was comparable to the effect displayed by CEPA, with a 115-
fold increase in the Kiyo and a ΔΔGay of −1.95 kcal/mol, each relative to wild type (Table 3-
1).  Though, methyl-malonic acid results were similar to CEPA, the error was greatly 
increased for these experiments and could not be reduced.  The first group of ligands 
intended to look at phosphorylated ligand requirements clearly indicate that phosphate is 
required for binding and allostery.  To test the ability of phosphate alone to elicit allosteric 
response in EcPFK, inorganic phosphate (Pi) was examined.  Pi has a Kiyo around 51-fold the 
 73 
 
 
Figure 3-10: Structures of the natural activator, ADP (A), and the activator analogs 
GDP (B), IDP (C), and UDP (D). 
 
 
 
Table 3-2: Comparison of the natural activator, MgADP, to the activator analogs that 
have been examined.  All data were collected at a pH of 8.0 and 25°C.   
A B!
C D
Table 3-2: 
Ligand Kix
0 !
(mM) Qax  
ΔGix  
(kcal/mol) 
MgADP 0.073 ± 0.004 11.0 ± 0.2 -1.41 ± 0.03 
MgGDP 0.24 ± 0.01 14.2 ± 0.4 -1.57 ± 0.04 
MgIDP 0.22 ± 0.01 17.0 ± 0.5 -1.67 ± 0.05 
MgUDP 0.85 ± 0.03 13.2 ± 0.3 -1.53 ± 0.03 
Mg-dADP 0.027 ± 0.01 11.6 ± 0.1 -1.45 ± 0.01 
MgAMP 3.7 ± 0.4 1.8 ± 0.1 -0.35 ± 0.02 !
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Kiyo of PEP.  ΔΔGay is -2.03 kcal/mol relative to PEP and EcPFK (Table 3-1, Figure 3-6).  
The Pi experiments suggest that phosphate alone is enough to elicit a small inhibitory 
allosteric effect.   
A number of MgADP analogs were also examined for their ability to delineate the 
contributions of functional groups to allostery and ligand binding.  The first functional 
groups examined were those that belong to the nitrogenous base moiety.  The base analogs 
examined were Mg2+ guanosine 5’ diphosphate (MgGDP), Mg2+ inosine 5’ diphosphate 
(MgIDP), and Mg2+ uridine 5’ diphosphate (MgUDP) (Figure 3-10).  The two analogs 
consisting of purine rings, MgGDP and MgIDP, examine the importance of the functional 
groups and their arrangement on the base moiety.  Both MgGDP and MgIDP display a Kixo 
3-fold higher than MgADP with wild type EcPFK.  MgADP has a Kixo of 73 µM while the 
Kixo for MgGDP and MgIDP are each around 230 µM.  The ΔGax for both MgGDP and 
MgIDP remains comparable to the natural analog (Table 3-2, Figure 3-11). Experimental 
results with MgUDP are intended to examine the need for a purine base versus a pyrimidine 
base.  MgUDP also results in a comparable ΔGax value but exhibits a larger change in Kixo 
than the two purine analogs.  MgUDP has an increased Kixo of approximately 11.6-fold that 
of MgADP (Kd=850 µM) (Table 3-2, Figure 3-11).  Overall, the nitrogenous base moiety 
appears to only impact ligand binding in a significant manner.  
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Figure 3-11: F6P K1/2 versus [X] or [X’] plots.  MgADP (red filled circles), MgGDP 
(blue squares), MgIDP (green diamonds), MgUDP (orange triangles), MgdADP (purple 
triangles), and MgAMP (light blue circle outlines) are all represented.  The lines 
represent the best fit to equation 3-1 for each allosteric ligand.
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The next group of analogs were selected based on the positioning of MgADP and 
PEP when they are bound in the effector binding site of EcPFK, as discussed earlier in this 
chapter and in chapter 2.  The analogs Mg 2’-deoxy-adenosine diphosphate (Mg-dADP) and 
α-β-methylene-adenosine diphosphate (MgAMPCP) were examined (Figure 3-12).  The 
absence of the hydroxyl group at the 2’ position of Mg-dADP represents one of the 
functional groups that could be potentially interacting with the same residues that the 
methylene and/or carboxylate groups of PEP interact with, i.e. K214 and R54.  MgAMPCP 
possesses a carbon substitution where normally an oxygen bridges α and β phosphates of 
ADP.  Mg-AMPCP represents a change in the structure of MgADP where it would 
potentially interact with serine 58 of EcPFK.  Mg-dADP has a methylene deletion, similar to 
the PEP analog PG, and retains a highly comparable ΔGax to that of MgADP.  Differing from 
the homologous PEP analog, Mg-dADP retains a highly comparable Kixo.  MgAMPCP 
results presented the opposite results of Mg-dADP.  MgAMPCP did not yield observable 
binding or coupling.  MgAMPCP results indicate that the electronic and/or physical 
characteristics are so drastically different from MgADP that no binding is observable. 
Next, the necessity of phosphate was determined for MgADP.  Two analogs were 
used to examine the necessity of the presence of phosphate as well as specific need of 
diphosphate.  Adenosine represents the removal of all phosphate, while Mg2+ adenosine 
monophosphate (MgAMP) represents the removal of only one phosphate (Figure 3-12).  
Experiments with adenosine did not yield any observable binding or coupling.  The complete 
removal of phosphate clearly abolishes binding.  Unlike adenosine, AMP did exhibit the 
ability to allosterically activate EcPFK.  AMP displayed a Kixo 50-fold higher than that of 
MgADP.   
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Figure 3-12: Structures of the natural activator, ADP (A), and the activator analogs 
dADP (B), AMPCP (C), AMP (D), and Adenosine (E). 
A B!
C D
E!
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Allosteric coupling was also greatly impacted, giving ΔΔGax that is +1.07 kcal/mol  
MgADP (Table 3-2, Figure 3-11).  Though adenosine could only imply that phosphate is 
required for binding, MgAMP allows for the conclusion that the presence of at least 
monophosphate is necessary for binding and allostery.  MgAMP also indicates that the 
removal of a phosphate from the diphosphate of MgADP significantly impacts both ligand 
binding and allostery. 
Mutations 
In examining the results of the analog effector studies for PEP and MgADP, at least 
one strong conclusion may be drawn.  At least one phosphate group is required for the 
binding of both the inhibiting and activating allosteric effectors.  When considering the 
MgADP analog results alone, the changes to the diphosphate moiety gave the most drastic 
changes in binding, while changes to the nucleoside moiety had relatively small impacts on 
binding and allostery.  This phosphate centric theme is also seen in the results of the PEP 
analog experiments.  The analog PG, where the methylene group of PEP is deleted, yields 
minimal impact on binding and allostery.  Other PEP analogs that focused on changes 
involving the phosphate have more substantial impact on binding and allostery.  Overall, the 
analog studies suggest that the portions of the effector molecules closest to the phosphate 
groups have a greater impact on binding and coupling.  The EcPFK activated ternary 
complex (EcATC) and EcPEP crystal structures strengthen such a conclusion due to the high 
similarity of positioning seen between MgADP and PEP when bound in the allosteric binding 
pocket.  As discussed previously, the two allosteric effectors align very similarly and use 
many of the same binding residues in the EcPFK allosteric binding site.   
 
 79 
 
 
 
 
 
Table 3-3: Comparison of wild type EcPFK to the position 58 mutant EcPFK that have 
been examined.  All data was collected at a pH of 8.0 and 25°C.  
Table 3-3: 
Mutant  (mM)  (mM) Qax  (kcal/mol) 
 (mM) Qiy  (kcal/mol) 
WT 0.408 ± 0.003 
0.073 
± 0.004 
11.0 
± 0.2 
−1.41 
± 0.003 
0.41 
± 0.01 
0.0111 
± 0.0002 
+2.66 
± 0.05 
S58A 0.398 ± 0.002 
0.25 
± 0.01 
11.6 
± 0.3 
−1.45 
± 0.06 
0.41 
± 0.01 
0.04 
± 0.03 
+1.9 
± 1.8 
S58C 0.442 
± 0.006 
0.038 
± 0.001 
5.58 
± 0.08 
−1.02 
± 0.01 
12 
± 1 
0.38 
± 0.02 
+0.57 
± 0.03 
S58D 0.339 ± 0.003 − 1 − − 1 − 
S58N 0.550 ± 0.004 
2.8 
± 0.1 
3.75 
± 0.07 
−0.78 
± 0.1 
67 
± 30 
0.06 
± 0.3 
+1.6 
± 8.3 
S58K 9.4 ± 0.2 − 1 − − 1 − !
K 0ia Kix0 ΔGax Kiy0 ΔGay
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For the reasons mentioned in the previous paragraph, residues were identified that are 
thought to interact with the portions of the allosteric ligands closest to the phosphate groups.  
Although there are several residues seen interacting with the phosphate groups of PEP and 
MgADP, in this study serine 58 was selected for mutation and kinetic study.  S58 was 
selected because when its interactions are compared between EcPEP and EcATC, it can be 
seen interacting in two different ways.  In EcPEP S58 is seen interacting with the bridging 
oxygen of PEP.  In EcATC S58 is primarily seen interacting with the β phosphate of 
MgADP.  Although S58 is still in position to interact with the α-β bridging oxygen of 
MgADP it does not.  This apparent preferential treatment by S58 led to its selection as the 
focus of the mutation studies for the following experiments. 
Using a series of both conservative and non-conservative mutations in the presence of 
each of the natural effector ligands, serine 58 was examined for its role in the allosteric 
phenomenon.  Alanine, cysteine, aspartate, asparagine, and lysine were all substituted at 
residue position 58.  The first mutation examined was S58A.  The alanine substitution is an 
attempt to disrupt any potential interaction with the bridging oxygen of the allosteric ligands 
by deleting the hydroxyl group supplied by serine.  The Kiyo for PEP increased 88-fold, and 
reduced the coupling free energy by −0.71 kcal/mol from of that seen in wild type EcPFK.  
Alternatively, experiments with S58A mutation and MgADP, show the Kixo is increased by 
only 3-fold and displays no change in the allosteric coupling (Table 3-3, Figure 3-13).   
In an attempt for a more conservative mutation, the S58C mutant was examined.  Cysteine 
allows for the removal of the serine hydroxyl and replaces it with an alternative sulfhydryl.  
Results with PEP and S58C reveal a 30-fold increase to Kiyo compared to wild type EcPFK.  
Allosteric coupling is also negatively impacted, with a ΔΔGayo of −2.09  
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Figure 3-13: F6P K1/2 versus [X] or [Y] plots.  Wild Type EcPFK (red circles), S58A 
(blue squares), S58C (green diamonds), S58D (orange triangles), and S58N (purple 
triangles) are all represented.  PEP points are represented by solid shapes and MgADP 
is represented by shape outlines.  The lines represent the best fit to equation 3-1 for 
each allosteric ligand. 
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kcal/mol, relative to wild type.  When MgADP was examined with S58C, the mutant shows a 
50% decrease in Kixo.  While the S58C mutation has a positive impact on ligand binding, it 
yields a ΔΔGax that is +0.40 kcal/mol of that seen in the wild type enzyme.  Further probing 
the type of interaction in which serine 58 is participating, S58N was also selected for study.  
The substitution to asparagine potentially provides a hydrogen for hydrogen bond 
interactions.  For PEP, S58N displays a large impact on binding and coupling free energy, 
with a Kiyo increased over 160-fold and a ΔΔGay of −1.00 kcal/mol.  Allosteric coupling for 
MgADP is also dramatically decreased with a difference in coupling free energy of +0.63 
kcal/mol from WT EcPFK wild type.  While binding of MgADP is significantly impacted, 
the Kixo is only increased by 38-fold.  Both aspartate and lysine mutants yield no observable 
results with either PEP or MgADP (Table 3-3, Figure 3-13). 
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Conclusion 
Analysis of PPA and CEPA give insight into contributions of both the bridging 
oxygen and methylene group.  Relative to PEP both analogs had a large, but comparable to 
each other, reduction in allosteric coupling.  Binding analysis reveals notable decreases in 
affinity, but a much larger impact is observed with CEPA.  PPA and CEPA are phosphonic 
acids and have a deletion of the methylene group, relative to PEP.  The two analogs differ 
from one another only in the number of carbons, PPA with two and CEPA with three.  The 
three carbons present give CEPA five bonds from a carboxylic oxygen to a phosphonic 
oxygen making it a potential better match with PEP (Figure 3-7).  Without individually 
isolating the structural changes in PPA and CEPA, the disturbances of binding or coupling 
cannot be attributed to any one functional group.  Although, we are careful to note that when 
comparing the results between CEPA and PPA, only affects on ligand binding differed.  A 
decrease in ligand affinity and no change in coupling for CEPA could be a result of an 
extended freedom of movement for the carboxyl group of the ligand.  The double bonded 
methylene present in PEP can restrict conformations of the ligand.  Since methylene is absent 
in both CEPA and PPA the potential freedom of movement is increased.  The third carbon on 
CEPA could enable more conformations, versus PPA, during a binding event resulting in a 
reduction of binding affinity.   
The individual studies of the bridging oxygen and methylene group were achieved 
with the use of three additional analogs.  Results from PG, methylene minus analog, yield a 
notable penalty on binding affinity with relatively no change in allosteric coupling.  With no 
other structural difference relative to PEP, the results imply a strong role in ligand binding 
and little to no role in allosteric coupling for the methylene group.  PG analysis also further 
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supports the explanation given above for differences seen in binding between CEPA and 
PPA.  Change to the bridging oxygen is represented in the analog PMAA.  When carbon is 
substituted for the bridging oxygen, as in PMAA, the observable allosteric coupling is all but 
destroyed and binding affinity is greatly weakened.  The lack of allostery seen with PMAA 
could be a result steric clash due to the bond angle of carbon at the bridging oxygen position 
combined with the presence of the methylene double bond.  The restriction of conformations 
due to steric conflicts could potentially result in non-preferred ligand conformations.  Given 
the structural similarity to analogs previously mentioned, PMAA does not necessarily clarify 
the role of the bridging oxygen but rather further supports the importance of methylene to 
ligand binding. 
Given the positioning of MgADP in the binding pocket the results with MgGDP and 
MgIDP are not surprising.  Modifications of the nitrogenous base moiety resulted in minor 
impacts on binding and virtually no impact on allosteric activity.  When MgADP analogs 
MgAMPCP results indicate that the electronic and/or physical characteristics are so 
drastically different from MgADP that no binding is possible. 
Like PEP, the necessity of phosphate was determined for MgADP.  Two were used to 
examine the necessity of the presence of phosphate as well as specific need of diphosphate.  
Adenosine represents the removal of all phosphate, while Mg2+ adenosine monophosphate 
(MgAMP) represents the removal of only one phosphate. 
Mutations of residues at position 58 of EcPFK further support the hypothesis of 
allosteric site interaction with the bridging oxygen.  The analysis of PEP with an alanine 
substitution at position 58 results in a large penalty on both ligand binding and coupling.  The 
detrimental affect on PEP inhibition by S58A shows similarities to observations with the 
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bridging oxygen analogs.  A large affect on both coupling and binding, with a seemingly 
larger impact on coupling, again suggests the involvement of the of Ser58’s hydroxyl group 
with the bridging oxygen.  With a cysteine substitution at the 58 position a notable, but 
smaller, decrease in ligand affinity observed along with some gain of allosteric coupling, 
relative to S58A.  The relative gain in coupling observed with cysteine could be due to its 
hydrogen bonding potential of the residue.  The potential cysteine as a hydrogen bond donor 
could also explain S58C’s display tighter binding for PEP relative to alanine.  We also note 
that S58C shows a much larger affect on coupling relative to ligand binding.  In the case of 
S58C the 12x increase of Kiyo, relative to wild type, is still a much higher affinity than what 
is seen with any of the bridging oxygen analogs in this study. 
Mutations at position 58 also display the ability to differentiate between MgADP and 
PEP.  S58A displays a small decrease in ligand affinity for MgADP while having no impact 
on MgADP coupling.  S58C increases the binding affinity for MgADP and has a small 
decrease in MgADP coupling.  The differential treatment between allosteric activator and 
inhibitor by the EcPFK mutants demonstrates that activation and inhibition are two separate 
phenomena.  While sharing a ligand binding site certainly suggests that the same residues 
interacting in one allosteric event are used in the other, our data shows the ability of the 
enzyme to reassign roles in response to an effector ligands identity. 
The mechanism by which EcPFK differentiates between PEP and MgADP as 
inhibitor and activator, respectively, remains unresolved.  Previous data, along with the 
recently solved PEP bound EcPFK crystal structure, have implicated the interaction of 
effector site residue Ser58, located in α-helix 6, with the oxygen that bridges phosphate to 
carbon in PEP.  The study of the EcPFK mutant S58A, not only supported the hypothesis of 
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the existence of this interaction but unexpectedly demonstrated the enzyme’s ability to 
differentiate between the two native ligands .  Alanine, which served as essentially a 
hydroxyl deletion, caused the near disappearance of allosteric inhibition along with a 88x 
increase in PEP dissociation constant.  However, with MgADP, S58A had no affect on 
allosteric coupling and only a 3x increase in dissociation constant.  In the study presented 
here we analyze additional mutations at the serine 58 postion of EcPFK using 
thermodynamic linkage analysis. 
The ability to differentiate between binding and coupling, via thermodynamic linkage 
analysis, allows for the assignment of roles to ligand functional groups.  Use of linkage 
analysis with effector ligand analogs, limited to minor modifications, allows for role 
assignment of the methylene and bridging oxygen of PEP.  Methylene appears to primarily 
make contributions to ligand binding.  The bridging oxygen makes a large contribution to 
allosteric coupling while also making a small contribution to ligand binding.  Known 
structural data of EcPFK suggests that serine 58 is a primary residue of interaction for the 
bridging oxygen.  Mutations at this residue position further support the hypothesis of 
interaction between Ser58 and bridging oxygen.  Ser58 also demonstrates the ability to 
differentiate between allosteric activator and allosteric inhibitor. 
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4. CONCLUSION  
 
 
 
While there is no doubt that, in a fast paced industry, high throughput design has 
great merit, there has never been a more obvious need for a thorough understanding of 
allostery.  More specifically, there is a need to better understand the effect of allosteric ligand 
structure on the characteristics of the resulting allosteric behavior.  The relationship between 
ligand structure and allosteric function is key to the advancement of allosteric based 
pharmaceutics.   
Here I attempt to better understand the relationship between allosteric ligand structure 
and the resulting allosteric behavior by investigating the roles that functional groups and 
structure play in the binding affinity and allosteric potency of ligands at the allosteric site of 
phosphofructokinase from E. coli (EcPFK).  EcPFK catalyzes the conversion of fructose-6-
phosphate (F6P) into fructose-1,6-bisphosphate (FBP) via phosphoryl transfer from MgATP. 
EcPFK is allosterically inhibited and activated in the presence of phospho-enol-pyruvate 
(PEP) and MgADP, respectively. EcPFK also displays very strong homotropic coopertivity 
towards F6P.   Both activator and inhibitor have been shown to bind to the same effector site 
and result in only K-type effects [8,9].  The fact that both MgADP and PEP bind to the same 
binding site using a majority of the same residues, makes EcPFK an ideal system for this 
type of allosteric characterization.   
In chapter II, I disclose study of the crystal structure of EcPFK that has been solved 
with PEP bound to the allosteric binding sites (EcPEP).  Over the years, the allosteric 
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behavior of EcPFK has been speculated to be the result of a shift of its overall structure from 
an activated state to an inhibited state.  A two state type model for allosteric behavior places 
inherent limits on the variation of characteristics observed for one allosteric ligand versus 
another.  The flipping from one state to another implies that a ligand needs only a minimum 
structural requirement to stabilize a particular state.  Much of this speculation stems from the 
two published crystal structures of EcPFK and the earlier crystal structures of its homolog, B. 
stearothermophilus (BsPFK) (52-54).  The known EcPFK publications represent the enzyme 
in the apo form (EcApo) and the activated ternary complex form (EcATC).  The EcATC is 
bound to FBP and MgADP in the active site, as well as MgADP in the effector site (55, 56).  
Thermodynamic linkage analysis allows the consideration of the enzymatic forms set forth 
by the disproportionation equilibrium in figure 1.  In this scheme EcApo represents “E”, 
EcATC represents one of two possible “XEA”.  Chapter II presents the first study of EcPEP, 
the only known binary complex of EcPFK, which represents one of two possible “XE” forms 
of EcPFK. 
Chapter III is a thorough kinetic characterization of the coupling between fructose-6-
phosphate (F6P) and allosteric effector analogs.  The resulting study suggests the role of 
functional groups belonging to allosteric ligands.    Different effector analogs that vary only 
slightly from the natural allosteric effectors EcPFK were utilized so that the minor 
modifications allow for meaningful comparisons of the parameters obtained via 
thermodynamic linkage analysis with F6P and allosteric ligand.   Comparison of dissociation 
constants (Kd) between the effectors and effector analogs allows for a direct analysis of the 
affects on binding affinity by the variation present, whereas the comparison of the coupling 
quotient (Qax) yields the impact on allosteric response.  Chapter III further interrogates the 
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interactions between ligand and protein via modification of effector site residues.  In 
retrospect, one could reason that the ligand analog study mentioned in the previous paragraph 
entailed the “mutation” of effector ligands in order to differentiate the functional constituents 
from their molecular structure.   Using the information obtained from the ligand analog study 
along with what is known about the effector binding site, more conclusions were made about 
ligand-residue interactions in the effector site.  Modification of ligand interacting residues 
results in altered allosteric response in a manner comparable to those seen with the modified 
effectors and wild type enzyme.    
A fundamental step in hypothesis development is the accurate characterization of the 
subject.  The two state Model has been used to characterize the previously known crystal 
structures of EcPFK and BsPFK (52-56). Not only has EcATC been characterized as the R-
State enzyme but also EcApo (55, 56).  A closer examination of thermodynamic linkage 
analysis, presented in chapter I, shows that the disproportionation reaction represents a much 
more accurate depiction of the species of enzymes discussed in this dissertation.  The 
disproportionation reaction describes the equilibrium between the two binary complexes, i.e. 
the enzyme bound to substrate (EA) or allosteric effector (XE), on one side of the 
equilibrium and on the other side is the apo enzyme (E) and the ternary complex (XEA), i.e. 
where both substrate and allosteric ligand are bound.  When accounting for the 
disproportionation equilibrium, the known crystal structures of EcPFK can be identified as a 
specific species and characterized independently of the other species.  Given the 
disproportionation equilibrium, EcPEP is the only known crystal structure of an EcPFK 
binary complex.  EcATC represents the ternary complex while EcApo represents the 
unbound enzyme. 
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Another fundamental step of hypothesis development is the application of concepts, 
models, and facts.  Hypotheses built on such strong foundations lead the way for exceptional 
research and experiments.  A fundamental element of a hypothesis is the remembrance that it 
is an educated guess.  One cannot perpetuate a hypothesis as fact.  In this chapter we have 
shown that BsPG is, structurally, very different from EcPEP.  The differences between BsPG 
and EcPEP should not be a surprise since BsPFK and EcPFK are different proteins.  Though 
these two bacterial PFKs share a 55% amino acid identity, they also have markedly different 
kinetics and thermodynamic parameters.  The differences BsPG and EcPEP are largely due to 
the difference in amino acid sequences, but it should not be forgotten that PG is an analog of 
the natural allosteric inhibitor for both enzymes.   
Thermodynamic linkage analysis provides for the identification of another difference 
between EcPFK and BsPFK, the component contributions of ΔGax.  Since Qax is an 
equilibrium constant we can use it to calculate the free energy of the coupling between A and 
X.  For allosteric inhibition, Qax is less than 1 and is ΔGax positive.  Allosteric activation 
yields a Qax value greater than 1 and a negative ΔGax.  By examining the temperature 
dependencies of coupling for BsPFK and EcPFK in van’t Hoff analyses, equation 2-1 can be 
utilized to determine the enthalpic and entropic contributions to ΔGax (86).   
Since equation 2-1 states that ΔHax and TΔSax oppose one another, if ΔGax retains the sign of 
ΔHax then it is considered enthalpically dominated.   Oppositely, when ΔGax retains the sign 
of TΔSax then ΔGax is entropically dominated.   When previously studied, ΔGax for EcPFK 
was shown to be enthalpically (ΔHax) dominated with respect to both allosteric ligands, 
MgADP and PEP (18, 69).  The same type of study has shown that BsPFK is dominated by 
its entropic component (TΔSax) for both allosteric ligands (17, 70).  When considering the 
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thermodynamic origins of allosteric coupling along with all of the data presented in this 
chapter, the use of BsPG as a substitute structure for EcPEP is fundamentally wrong. 
Analysis of PPA and CEPA gave insight into contributions of both the bridging 
oxygen and methylene group.  Relative to PEP both analogs had a large, but comparable to 
each other, reduction in allosteric coupling.  Binding analysis reveals notable decreases in 
affinity, but a much larger impact is observed with CEPA.  PPA and CEPA are phosphonic 
acids and, relative to PEP, have a deletion of the methylene group.  The two analogs differ 
from one another only in the number of carbons, PPA with two and CEPA with three.  The 
three carbons present give CEPA five bonds from a carboxylic oxygen to a phosphonic 
oxygen making it a potential better match with PEP.  Without individually isolating the 
structural changes in PPA and CEPA, the disturbances of binding or coupling cannot be 
attributed to any one functional group.  Although, we are careful to note that when 
comparing the results between CEPA and PPA, only affects on ligand binding differed.  A 
decrease in ligand affinity and no change in coupling for CEPA could be a result of an 
extended freedom of movement for the carboxyl group of the ligand.  The double bonded 
methylene present in PEP can restrict conformations of the ligand.  Since methylene is absent 
in both CEPA and PPA the potential freedom of movement is increased.  The third carbon on 
CEPA could enable more conformations, versus PPA, during a binding event resulting in a 
reduction of binding affinity.   
The individual studies of the bridging oxygen and methylene group were achieved 
with the use of three additional analogs.  Results from PG, methylene minus analog, yield a 
notable penalty on binding affinity with relatively no change in allosteric coupling.  With no 
other structural difference relative to PEP, results imply a strong role in ligand binding and 
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little to no role in allosteric coupling for the methylene group.  PG analysis also further 
supports the explanation given above for differences seen in binding between CEPA and 
PPA.  Change to the bridging oxygen is represented in the analog PMAA.  When carbon is 
substituted for the bridging oxygen, as in PMAA, the observable allosteric coupling is all but 
destroyed and binding affinity is greatly weakened.  The lack of allostery seen with PMAA 
could be a result steric clash due to the bond angle of carbon at the bridging oxygen position 
combined with the presence of the methylene double bond.  The restriction of conformations 
due to steric conflicts could potentially result in non-preferred ligand conformations.  Given 
the structural similarity to analogs previously mentioned, PMAA does not necessarily clarify 
the role of the bridging oxygen but rather further supports the importance of methylene to 
ligand binding. 
Given the positioning of MgADP in the binding pocket the results with MgGDP and 
MgIDP are not surprising.  Modifications of the nitrogenous base moiety resulted in minor 
impacts on binding and virtually no impact on allosteric activity.  When MgADP analogs 
Mg-αβADP results indicate that the electronic and/or physical characteristics are so 
drastically different from MgADP that no binding is possible. 
Like PEP, the necessity of phosphate was determined for MgADP.  Two were used to 
examine the necessity of the presence of phosphate as well as specific need of diphosphate.  
Adenosine represents the removal of all phosphate, while Mg2+ adenosine monophosphate 
(MgAMP) represents the removal of only one phosphate. 
Mutations of residues at position 58 of EcPFK further support the hypothesis of 
allosteric site interaction with the bridging oxygen.  The analysis of PEP with an alanine 
substitution at position 58 results in a large penalty on both ligand binding and coupling.  The 
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detrimental affect on PEP inhibition by S58A shows similarities to observations with the 
bridging oxygen analogs.  A large affect on both coupling and binding, with a seemingly 
larger impact on coupling, again suggests the involvement of the of Ser58’s hydroxyl group 
with the bridging oxygen.  With a cysteine substitution at the 58 position a notable, but 
smaller, decrease in ligand affinity observed along with some gain of allosteric coupling, 
relative to S58A.  The relative gain in coupling observed with cysteine could be due to its 
hydrogen bonding potential of the residue.  The potential cysteine as a hydrogen bond donor 
could also explain S58C’s display tighter binding for PEP relative to alanine.  We also note 
that S58C shows a much larger affect on coupling relative to ligand binding.  In the case of 
S58C the 12x increase of Kd, relative to wild type, is still a much higher affinity than what is 
seen with any of the bridging oxygen analogs in this study. 
Mutations at position 58 also display the ability to differentiate between MgADP and 
PEP.  S58A displays a small decrease in ligand affinity for MgADP while having no impact 
on MgADP coupling.  S58C increases the binding affinity for MgADP and has a small 
decrease in MgADP coupling.  The differential treatment between allosteric activator and 
inhibitor by the EcPFK mutants demonstrates that activation and inhibition are two separate 
phenomena.  While sharing a ligand binding site certainly suggests that the same residues 
interacting in one allosteric event are used in the other, our data shows the ability of the 
enzyme to reassign roles in response to an effector ligands identity. 
The mechanism by which EcPFK differentiates between PEP and MgADP as 
inhibitor and activator, respectively, remains unresolved.  Previous data, along with the 
recently solved PEP bound EcPFK crystal structure, have implicated the interaction of 
effector site residue Ser58, located in α-helix 6, with the oxygen that bridges phosphate to 
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carbon in PEP.  The study of the EcPFK mutant S58A, not only supported the hypothesis of 
the existence of this interaction but unexpectedly demonstrated the enzyme’s ability to 
differentiate between the two native ligands .  Alanine, which served as essentially a 
hydroxyl deletion, caused the near disappearance of allosteric inhibition along with a 88x 
increase in PEP dissociation constant.  However, with MgADP, S58A had no affect on 
allosteric coupling and only a 3x increase in dissociation constant.  In the study presented 
here we analyze additional mutations at the serine 58 postion of EcPFK using 
thermodynamic linkage analysis. 
The ability to differentiate between binding and coupling, via thermodynamic linkage 
analysis, allows for the assignment of roles to ligand functional groups.  Use of linkage 
analysis with effector ligand analogs, limited to minor modifications, allows for role 
assignment of the methylene and bridging oxygen of PEP.  Methylene appears to primarily 
make contributions to ligand binding.  The bridging oxygen makes a large contribution to 
allosteric coupling while also making a small contribution to ligand binding.  Known 
structural data of EcPFK suggests that serine 58 is a primary residue of interaction for the 
bridging oxygen.  Mutations at this residue position further support the hypothesis of 
interaction between Ser58 and bridging oxygen.  Ser58 also demonstrates the ability to 
differentiate between allosteric activator and allosteric inhibitor. 
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